WO2022259721A1 - 間葉系幹細胞の製造方法 - Google Patents
間葉系幹細胞の製造方法 Download PDFInfo
- Publication number
- WO2022259721A1 WO2022259721A1 PCT/JP2022/015032 JP2022015032W WO2022259721A1 WO 2022259721 A1 WO2022259721 A1 WO 2022259721A1 JP 2022015032 W JP2022015032 W JP 2022015032W WO 2022259721 A1 WO2022259721 A1 WO 2022259721A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- stem cells
- mesenchymal stem
- neural crest
- medium
- Prior art date
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 124
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 68
- 210000001982 neural crest cell Anatomy 0.000 claims abstract description 122
- 239000013028 medium composition Substances 0.000 claims abstract description 53
- 239000003814 drug Substances 0.000 claims abstract description 43
- 201000010099 disease Diseases 0.000 claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 37
- 238000012258 culturing Methods 0.000 claims abstract description 28
- 239000003470 adrenal cortex hormone Substances 0.000 claims abstract description 26
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000007640 basal medium Substances 0.000 claims abstract description 18
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 18
- 230000001939 inductive effect Effects 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 196
- 108010085895 Laminin Proteins 0.000 claims description 53
- 102000007547 Laminin Human genes 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 40
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 claims description 37
- 101710169430 Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 claims description 34
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 28
- 229960003957 dexamethasone Drugs 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 21
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 16
- 229960005205 prednisolone Drugs 0.000 claims description 16
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 16
- 229960002537 betamethasone Drugs 0.000 claims description 14
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 14
- 239000003862 glucocorticoid Substances 0.000 claims description 14
- 230000000638 stimulation Effects 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 230000004761 fibrosis Effects 0.000 claims description 12
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 210000002744 extracellular matrix Anatomy 0.000 claims description 11
- 239000012228 culture supernatant Substances 0.000 claims description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 229940126585 therapeutic drug Drugs 0.000 claims description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 229960000890 hydrocortisone Drugs 0.000 claims description 5
- 229960004584 methylprednisolone Drugs 0.000 claims description 5
- 229940043274 prophylactic drug Drugs 0.000 claims description 5
- 229960005294 triamcinolone Drugs 0.000 claims description 5
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 5
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- 229940092705 beclomethasone Drugs 0.000 claims description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 3
- 229960003290 cortisone acetate Drugs 0.000 claims description 3
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 claims description 3
- 229960003336 fluorocortisol acetate Drugs 0.000 claims description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 2
- 239000012679 serum free medium Substances 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 239000002609 medium Substances 0.000 description 72
- 230000004069 differentiation Effects 0.000 description 33
- 210000000130 stem cell Anatomy 0.000 description 22
- 230000001780 adrenocortical effect Effects 0.000 description 18
- 229940088597 hormone Drugs 0.000 description 18
- 239000005556 hormone Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 230000006698 induction Effects 0.000 description 15
- 230000003449 preventive effect Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000004114 suspension culture Methods 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 8
- 238000004115 adherent culture Methods 0.000 description 8
- 235000021186 dishes Nutrition 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000001082 somatic cell Anatomy 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 239000002121 nanofiber Substances 0.000 description 7
- 102100022464 5'-nucleotidase Human genes 0.000 description 6
- 102100032912 CD44 antigen Human genes 0.000 description 6
- -1 CD79 Proteins 0.000 description 6
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 6
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 6
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 6
- 230000004956 cell adhesive effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 102100037362 Fibronectin Human genes 0.000 description 5
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000001808 exosome Anatomy 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000007667 floating Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 102100037241 Endoglin Human genes 0.000 description 4
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 4
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 4
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108010038862 laminin 10 Proteins 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000011435 rock Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101000847156 Homo sapiens Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100037369 Nidogen-1 Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 108010008217 nidogen Proteins 0.000 description 3
- 229960002858 paramethasone Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 241000282405 Pongo abelii Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 229960002435 fasudil Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920002714 polyornithine Polymers 0.000 description 2
- 108010055896 polyornithine Proteins 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000002444 unipotent stem cell Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 1
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 102000010954 Link domains Human genes 0.000 description 1
- 108050001157 Link domains Proteins 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 206010048654 Muscle fibrosis Diseases 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150072008 NR5A2 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 201000004854 SAPHO syndrome Diseases 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 101150001847 Sox15 gene Proteins 0.000 description 1
- 101150012560 TNFAIP6 gene Proteins 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 101150111019 Tbx3 gene Proteins 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108010083162 Twist-Related Protein 1 Proteins 0.000 description 1
- 102100030398 Twist-related protein 1 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008190 early vertebrate development Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108010067471 inhibin A Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 206010065988 nodular fasciitis Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 230000002669 organ and tissue protective effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 201000006081 pseudosarcomatous fibromatosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Definitions
- the present invention relates to a method for producing mesenchymal stem cells, and more particularly to a method for producing mesenchymal stem cells using a medium composition containing a basal medium and adrenocortical hormones.
- Mesenchymal stem cells are a type of somatic stem cells that exist in the bone marrow of the living body, and are defined as adhesive cells that have the ability to differentiate into bone, cartilage, and adipocytes.
- Mesenchymal stem cells are considered to have an extremely low risk of becoming cancerous, and are highly promising as cell materials for use in regenerative medicine.
- mesenchymal stem cells accumulate at sites of tissue injury, release various humoral factors and exosomes, and have the function of regulating immune responses and anti-inflammatory effects, playing an important role in tissue repair and maintenance of homeostasis. is known to fulfill Therefore, mesenchymal stem cells themselves are also promising as cell preparations for treating immune diseases, inflammatory diseases, and the like.
- mesenchymal stem cells have different differentiation potential and growth/functional characteristics depending on the tissue from which they are derived, there is a demand for efficient production of mesenchymal stem cells that exhibit useful properties according to the purpose. had been
- Neural crest cells are peculiar to vertebrates. They are cells that differentiate into a wide variety of cells such as pigment cells. It was known that neural crest cells can be produced by the methods disclosed in Patent Document 1 and Non-Patent Document 1, and that differentiation of mesenchymal stem cells can be induced therefrom (Non-Patent Document 2). A more efficient method of producing the was being investigated.
- An object of the present invention is to provide a medium composition, a method for producing mesenchymal stem cells, and the like for efficiently producing mesenchymal stem cells.
- mesenchymal stem cells can be efficiently induced from neural crest cells by using a medium composition containing adrenocortical hormones, and the medium composition We have found suitable concentrations of adrenocortical hormones in the product. Furthermore, they found that mesenchymal stem cells obtained by culturing neural crest cells in such a medium composition highly express TSG-6 and are useful as a preventive or therapeutic agent for inflammatory diseases. rice field. In addition, the secretome of mesenchymal stem cells obtained by culturing neural crest cells in such a medium composition reduces the expression of fibrosis marker genes COL1A1 and ACTA2, thus preventing fibrotic diseases. Alternatively, the present invention was completed by discovering that it is useful as a therapeutic drug.
- a medium composition for inducing mesenchymal stem cells from neural crest cells containing a basal medium and an adrenocortical hormone, wherein the converted concentration of the adrenocortical hormone in the medium composition is 1.25 ⁇ M or more.
- a method for producing a drug for the prevention or treatment of inflammatory diseases or fibrotic diseases comprising the step of inducing mesenchymal stem cells by culturing neural crest cells in a medium composition.
- the prophylactic or therapeutic drug for inflammatory or fibrotic diseases contains mesenchymal stem cells characterized by high expression of TSG-6 as an active ingredient.
- a method for producing a drug for the prevention or treatment of an inflammatory disease further comprising recovering TSG-6 protein from the induced mesenchymal stem cells and/or the culture supernatant, The method of [1], wherein the prophylactic or therapeutic agent contains TSG-6 protein as an active ingredient.
- a method for producing a drug for the prevention or treatment of fibrotic diseases further comprising recovering a secretome from the induced mesenchymal stem cells and/or the culture supernatant, for the prevention or treatment of fibrosis The method of [1], wherein the drug contains the secretome as an active ingredient.
- [5] The production method according to any one of [1] to [4], wherein the adrenocortical hormone is a glucocorticoid or a derivative thereof.
- the glucocorticoid or its derivative is at least one selected from the group consisting of cortisone acetate, hydrocortisone, fludrocortisone acetate, prednisolone, triamcinolone, methylprednisolone, dexamethasone, betamethasone, and beclomethasone propionate. 5].
- [7] The production method of [5] or [6], wherein the glucocorticoid or derivative thereof is dexamethasone.
- iPS cells induced pluripotent stem cells
- [16] The method of [13] to [15], wherein the cell population containing neural crest cells obtained in step A is subjected to step B without being subjected to neural crest cell sorting treatment.
- [17] The production method according to any one of [1] to [3] and [5] to [16], wherein the inflammatory disease is liver cirrhosis.
- [18] The production method according to any one of [2], [3] and [5] to [17], wherein the high expression of TSG-6 is high expression in response to IFN ⁇ stimulation.
- a drug for the prevention or treatment of inflammatory diseases produced by the production method of any one of [1] to [3] and [5] to [18], or [1], [2], [4] A drug for preventing or treating a fibrotic disease, which is produced by the production method according to any one of to [18].
- the present invention it is possible to provide a medium composition for efficiently inducing mesenchymal stem cells from neural crest cells.
- a medium composition for efficiently inducing mesenchymal stem cells from neural crest cells there are provided an efficient method for producing mesenchymal stem cells, a preventive or therapeutic agent for inflammatory or fibrotic diseases containing the mesenchymal stem cells or the like as an active ingredient, and prevention of the disease.
- a therapeutic method a method for producing the therapeutic drug, and the like.
- FIG. 1 is a graph showing gene expression of TNFAIP6 (TSG-6) after stimulation with 50 ng/mL IFN ⁇ for 48 hours in various mesenchymal stem cells.
- FIG. 2 is a graph showing cell growth curves during induction of differentiation.
- FIG. 3 is a graph showing gene expression of TNFAIP6 (TSG-6) after stimulation with 50 ng/mL IFN ⁇ for 48 hours.
- FIG. 4 is a graph showing that the secretome isolated from the mesenchymal stem cells of the present invention significantly reduced the expression of fibrotic marker genes COL1A1 and ACTA2 in the LX-2 cell line.
- the present invention provides a medium composition for inducing mesenchymal stem cells from neural crest cells, containing a basal medium and an adrenocortical hormone, wherein the converted concentration of the adrenocortical hormone in the medium composition is 1.25.
- a culture medium composition (hereinafter also referred to as the culture medium composition of the present invention) is provided that is at least ⁇ M.
- the basal medium contained in the medium composition of the present invention can be a basal medium known per se, and is not particularly limited as long as it does not inhibit the induction of mesenchymal stem cells from neural crest cells.
- the basal medium includes, for example, IMDM medium, Medium199 medium, Eagle's Minimum Essential Medium (EMEM) medium, ⁇ MEM medium, Dulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium, StemPro34 (Invitrogen) , RPMI-base medium, StemFit (registered trademark), MCDB201 medium and mixed medium thereof.
- StemFit (registered trademark) medium is preferably used in this step.
- the medium may contain serum or may be serum-free. If necessary, the medium contains, for example, albumin, transferrin, Knockout Serum Replacement (KSR) (serum replacement for FBS during ES cell culture), N2 supplement (Invitrogen), B27 supplement (Invitrogen), fatty acids, insulin, collagen May contain one or more serum replacements such as precursors, trace elements, 2-mercaptoethanol (2ME), thiolglycerol, lipids, amino acids, L-glutamine, Glutamax (Invitrogen), non-essential amino acids, vitamins, It may also contain one or more substances such as growth factors, small molecules, antibiotics, antioxidants, pyruvate, buffers, inorganic salts, and the like.
- KSR Knockout Serum Replacement
- the medium contains adrenocortical hormones.
- Adrenal cortical hormones include, for example, glucocorticoids and derivatives thereof, and the glucocorticoids and derivatives thereof include, for example, cortisone, cortisone acetate, hydrocortisone, fludrocortisone acetate, paramethasone, prednisolone, triamcinolone, methyl Prednisolone, dexamethasone, betamethasone, beclomethasone propionate. Among these, prednisolone, dexamethasone and betamethasone are preferred, and dexamethasone is especially preferred.
- One or more adrenal corticosteroids may be added to the medium, but one is preferred.
- Dexamethasone (CAS number: 50-02-2, CA index name: Pregna-1,4-diene-3,20-dione,9-fluoro-11,17,21-trihydroxy-16-methyl-,(11 ⁇ ,16 ⁇ ) )-) is
- Dexamethasone It is a known synthetic adrenocortical hormone having a structure represented by Dexamethasone is commercially available and such commercial products can also be used in the present invention. Since differentiation of neural crest cells into mesenchymal stem cells is induced by using dexamethasone, mesenchymal stem cells can be produced with high efficiency by culturing neural crest cells in the medium composition of the present invention. be able to.
- the concentration of adrenocortical hormone contained in the medium composition is not particularly limited as long as it is a concentration that can promote the differentiation of neural crest cells into mesenchymal stem cells. ⁇ 50 nM (or >50 nM), ⁇ 55 nM (or >55 nM), ⁇ 60 nM (or >60 nM), ⁇ 65 nM (or >65 nM), ⁇ 70 nM (or >70 nM), ⁇ 75 nM (or >75 nM), ⁇ 80 nM (or >80 nM), ⁇ 85 nM (or >85 nM), ⁇ 90 nM (or >90 nM), ⁇ 95 nM (or >95 nM), ⁇ 100 nM (or >100 nM), ⁇ 150 nM (or >150 nM), ⁇ 200 nM (or >200 nM), ⁇ 250 nM (or >250 nM), ⁇ 300 nM (or >300
- an adrenocortical hormone other than dexamethasone is used, it is preferably used at a concentration that exhibits the same glucocorticoid potency as dexamethasone at the above concentration. Too low corticosteroid concentrations in the medium may not be sufficient to promote culture maintenance and mesenchymal stem cell induction, whereas too high corticosteroid concentrations inhibit cell proliferation and Mesenchymal stem cells cannot be obtained efficiently.
- the concentration of adrenocortical hormone contained in the medium composition is, for example, 50 nM to 10 ⁇ M (or 50 nM to 10 ⁇ M, 50 nM to 10 ⁇ M, or 50 nM to 10 ⁇ M), preferably 60 nM to 5 ⁇ M (or 60 nM to 5 ⁇ M, 60 nM to 5 ⁇ M, or 60 nM 5 ⁇ M), more preferably 70 nM to 2 ⁇ M (or 70 nM to less than 2 ⁇ M, 70 nM to 2 ⁇ M, or 70 nM to less than 2 ⁇ M), even more preferably 100 nM to 1 ⁇ M (or 100 nM more than 1 ⁇ M, more than 100 nM and less than 1 ⁇ M, or more than 100 nM and less than 1 ⁇ M).
- the potency of adrenocortical hormones as glucocorticoids is 0.8 for cortisone, 4 for prednisolone, 5 for methylprednisolone, 5 for triamcinolone, 10 for paramethasone, 25-30 for dexamethasone, and 25 for betamethasone when hydrocortisone is 1. ⁇ 30. If there is a possibility that the potency of each adrenocortical hormone as a glucocorticoid differs from the above value depending on the manufacturer or storage conditions, it should be experimentally confirmed in advance. It is desirable to use one in good condition.
- the concentration of betamethasone contained in the medium composition is not particularly limited as long as it can promote the differentiation of neural crest cells into mesenchymal stem cells. ⁇ 50 nM (or >50 nM), ⁇ 55 nM (or >55 nM), ⁇ 60 nM (or >60 nM), ⁇ 65 nM (or >65 nM), ⁇ 70 nM (or >70 nM), ⁇ 75 nM (or >75 nM), ⁇ 80 nM (or >80 nM), ⁇ 85 nM (or >85 nM), ⁇ 90 nM (or >90 nM), ⁇ 95 nM (or >95 nM), ⁇ 100 nM (or >100 nM), ⁇ 150 nM (or >150 nM), ⁇ 200 nM (or >200 nM), ⁇ 250 nM (or >250 nM), ⁇ 300 nM (or >100 nM (or >50 nM
- the concentration of betamethasone contained in the medium composition is, for example, 50 nM to 10 ⁇ M (or 50 nM to less than 10 ⁇ M, more than 50 nM to 10 ⁇ M , or 50 nM to less than 10 ⁇ M), preferably 60 nM to 5 ⁇ M (or 60 nM to less than 5 ⁇ M, 60 nM to 5 ⁇ M, or 60 nM to less than 5 ⁇ M), more preferably 70 nM to 2 ⁇ M (or 70 nM to less than 2 ⁇ M, 70 nM to 2 ⁇ M, or 70 nM to less than 2 ⁇ M), even more preferably 100 nM to 1 ⁇ M (or 100
- the concentration of prednisolone contained in the medium composition is not particularly limited as long as it can promote the differentiation of neural crest cells into mesenchymal stem cells. ⁇ 300 nM (or >300 nM), ⁇ 330 nM (or >330 nM), ⁇ 360 nM (or >360 nM), ⁇ 390 nM (or >390 nM), ⁇ 420 nM (or >420 nM), ⁇ 450 nM (or >450 nM), ⁇ 480 nM (or >480 nM), ⁇ 510 nM (or >510 nM), ⁇ 540 nM (or >540 nM), ⁇ 570 nM (or >570 nM), >600 nM (or >600 nM), >900 nM (or >900 nM), >1.2 ⁇ M (or >1.2 ⁇ M), >1.5 ⁇ M (or >1.5 ⁇ M), >1.8 ⁇ M (or
- the concentration of prednisolone contained in the medium composition is, for example, 300 nM to 70 ⁇ M (or 300 nM to less than 70 ⁇ M, more than 300 nM to 70 ⁇ M , or 300 nM to less than 70 ⁇ M), preferably 360 nM to 35 ⁇ M (or 360 nM to less than 35 ⁇ M, 360 nM to 35 ⁇ M, or 360 nM to less than 35 ⁇ M), more preferably 420 nM to 14 ⁇ M (or 420 nM to 14 ⁇ M, 420 nM to 14 ⁇ M, or 420 nM to 14 ⁇ M), even more preferably 600 nM to 7
- the concentration of adrenocortical hormones contained in the medium composition is 50 nM or more and 10 ⁇ M or less for dexamethasone or betamethasone (or 50 nM or more and less than 10 ⁇ M, or more than 50 nM when each one is used alone).
- paramethasone is 100 nM to 30 ⁇ M, Triamcinolone or methylprednisolone 250 nM to 60 ⁇ M (or 250 nM to ⁇ 60 ⁇ M, 250 nM to 60 ⁇ M, or 250 nM to less than 60 ⁇ M) and prednisolone 300 nM to 70 ⁇ M (or 300 nM >70 ⁇ M, >300 nM and ⁇ 70 ⁇ M, or >300 nM and ⁇ 70 ⁇ M) and cortisone >1.50 ⁇ M and ⁇ 375 ⁇ M (or >1.50 ⁇ M and ⁇ 375 ⁇ M, >1.50 ⁇ M and ⁇ 375 ⁇ M, or 1.50 ⁇ M) >375 ⁇ M) and hydrocortisone >1.250 ⁇ M and ⁇ 300 ⁇ M (or >1.250 ⁇ M and ⁇ 300 ⁇ M, >1.250 ⁇ M and ⁇
- the concentration of adrenocortical hormones contained in the medium composition is 50 nM or more and 375 ⁇ M or less (or 50 nM or more and less than 375 ⁇ M, 50 nM or more and 375 ⁇ M or less, or more than 50 nM and less than 375 ⁇ M).
- the concentration of the adrenocortical hormone is multiplied by the potency of the glucocorticoid, and the sum of the concentrations is added to the one or more adrenocortical hormones.
- the converted concentration is, for example, 1.25 ⁇ M or more (or 1.25 ⁇ M or more), 1.375 ⁇ M or more (or 1.375 ⁇ M or more), 1.5 ⁇ M or more (or 1.5 ⁇ M or more), 1.625 ⁇ M or more (or 1.625 ⁇ M or more ⁇ M), ⁇ 1.75 ⁇ M (or >1.75 ⁇ M), ⁇ 1.875 ⁇ M (or >1.875 ⁇ M), ⁇ 2 ⁇ M (or >2 ⁇ M), ⁇ 2.125 ⁇ M (or >2.125 ⁇ M), ⁇ 2.25 ⁇ M (or 2.25 ⁇ M), ⁇ 2.375 ⁇ M (or >2.375 ⁇ M), ⁇ 2.5 ⁇ M (or >2.5 ⁇ M), ⁇ 3.75 ⁇ M (or >3.75 ⁇ M), ⁇ 5 ⁇ M (or >5 ⁇ M), ⁇ 6.25 ⁇ M (or 6.25 ⁇ M), ⁇ 7.5 ⁇ M (or >7.5 ⁇ M), ⁇ 8.75 ⁇ M (
- the equivalent concentration of adrenocortical hormones is 1.25 ⁇ M to 300 ⁇ M (or 1.25 ⁇ M to less than 300 ⁇ M, 1.25 ⁇ M to 300 ⁇ M, or 1.25 ⁇ M to less than 300 ⁇ M).
- 1.5 ⁇ M to 150 ⁇ M (or 1.5 ⁇ M to less than 150 ⁇ M, more than 1.5 ⁇ M to 150 ⁇ M, or more than 1.5 ⁇ M to less than 150 ⁇ M), more preferably 17.5 ⁇ M to 60 ⁇ M (or 17.5 ⁇ M to less than 60 ⁇ M, more than 17.5 ⁇ M 60 ⁇ M or less, or 17.5 ⁇ M or more and less than 60 ⁇ M), still more preferably 2.5 ⁇ M to 30 ⁇ M (or 2.5 ⁇ M or more and less than 30 ⁇ M, 2.5 ⁇ M or more and 30 ⁇ M or less, or 2.5 ⁇ M or more and less than 30 ⁇ M).
- the medium composition of the present invention may contain serum.
- Serum is not particularly limited as long as it is animal-derived serum as long as it does not inhibit the induction of mesenchymal stem cells, but mammal-derived serum (eg, fetal bovine serum, human serum, etc.) is preferred.
- the concentration of serum may be within a concentration range known per se.
- serum-free media should also be preferably used, as other animal-derived components may serve as a source of infection for blood-borne pathogens or as xenoantigens. obtain.
- alternative additives for serum eg, Knockout Serum Replacement (KSR) (Invitrogen), Chemically-defined Lipid concentrated (Gibco), etc.
- mesenchymal stem cells induced and cultured by the medium composition of the present invention When mesenchymal stem cells induced and cultured by the medium composition of the present invention are used for medical purposes such as cell therapy, they may be infected with pathogens or become heterologous antigens. More preferably, the medium does not contain non-human animal-derived components.
- Stem cells means immature cells with self-renewal and differentiation/proliferation abilities. Stem cells include subpopulations such as pluripotent stem cells, multipotent stem cells, and unipotent stem cells, depending on their differentiation potential.
- a pluripotent stem cell means a cell that has the ability to differentiate into all tissues and cells that constitute a living body.
- Multipotent stem cells refer to cells that have the ability to differentiate into multiple, but not all, types of tissues and cells.
- a unipotent stem cell means a cell that has the ability to differentiate into a specific tissue or cell.
- Mesenchymal stem cells targeted in the present invention are a type of multipotent stem cells that can differentiate into adipocytes, osteocytes, chondrocytes, muscle cells, hepatocytes, nerve cells, etc. known as cells that are less likely to form
- the mesenchymal stem cells in the present invention are preferably positive for one or more mesenchymal stem cell markers (e.g., CD90, CD44, CD73, CD105, etc.), more preferably positive for the marker, and It may be negative for the expression of molecules that are not found to be expressed in foliar stem cells. Examples of molecules whose expression is not observed in mesenchymal stem cells include CD34, CD45, CD14, CD11b, CD79, CD19, HLA-DR and the like.
- the medium composition of the present invention can be suitably used for inducing mesenchymal stem cells derived from any animal.
- Mesenchymal stem cells that can be induced and cultured using the medium composition of the present invention include, for example, rodents such as mice, rats, hamsters and guinea pigs, lagomorphs such as rabbits, pigs, cattle, goats and horses. , ungulates such as sheep, felines such as dogs and cats, and mesenchymal stem cells derived from primates such as humans, monkeys, rhesus monkeys, marmosets, orangutans, and chimpanzees, preferably human-derived mesenchymal stem cells.
- stem cells preferably human-derived mesenchymal stem cells.
- the medium composition of the present invention contains factors that induce differentiation of mesenchymal stem cells (e.g., glucocorticoids, factors called transforming growth factor- ⁇ family, e.g., bone morphogenetic proteins (preferably BMP-2 or BMP-4). ), basic fibroblast growth factor (bFGF), inhibin A or chondrogenesis stimulating active factor (CSA), collagenous extracellular matrices such as type I collagen (especially in gel form), and vitamins such as retinoic acid. A analog), preferably at a concentration that does not induce differentiation of mesenchymal stem cells (eg, differentiation into cartilage).
- the medium may not contain factors that induce differentiation of mesenchymal stem cells other than adrenocortical hormones.
- the medium may not contain factors other than dexamethasone that induce differentiation of mesenchymal stem cells.
- the medium composition of the present invention may contain scaffolding components.
- the scaffold components include laminin [including laminin ⁇ 5 ⁇ 1 ⁇ 1 (hereinafter, laminin 511), laminin ⁇ 1 ⁇ 1 ⁇ 1 (hereinafter, laminin 111), etc. and laminin fragments (laminin 511E8, etc.)], entactin, fibronectin, gelatin, vitronectin, synthmax (Corning Co.), extracellular matrices such as Matrigel, etc., preferably laminin-511.
- These scaffold components are generally 0.001 ⁇ g/ml to 1000 ⁇ g/ml, preferably 0.01 ⁇ g/ml to 100 ⁇ g/ml, more preferably 0.1 ⁇ g/ml to 10 ⁇ g/ml, more preferably 0.1 ⁇ g/ml to 100 ⁇ g/ml. Add to medium at ⁇ g/ml to 1 ⁇ g/ml, most preferably 0.2 ⁇ g/ml.
- the medium composition of the present invention is used to induce differentiation of neural crest cells into mesenchymal stem cells.
- Nesenchymal stem cells also called “NCC”
- NCC neural Crest Cell
- the term "neural crest cells” as used herein includes not only cells collected from a living body, but also neural crest cells derived from pluripotent stem cells and subcultured cells thereof.
- the neural crest cells are not particularly limited in origin, and may be derived from any vertebrate, but neural crest cells derived from mammals are preferred. Such mammals include, but are not limited to, mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, sheep, pigs, cows, horses, goats, monkeys, and humans. Humans are preferred.
- Neural crest cells may be biologically-derived neural crest cells, for example, neural crest-derived tissues in vivo (e.g., bone marrow, dorsal root ganglion, heart, cornea, iris, dental pulp, olfactory mucosa, etc.). can be manufactured from Neural crest cells derived from pluripotent stem cells can also be preferably used.
- a method for obtaining neural crest cells from pluripotent stem cells a method known per se can be used.
- One example is culturing pluripotent stem cells in a culture medium containing a TGF ⁇ inhibitor and a GSK-3 ⁇ inhibitor.
- a method of inducing differentiation is exemplified.
- Whether or not the thus obtained cell population contains neural crest cells can be determined by confirming the expression of one or more neural crest cell-specific marker genes such as TFAP2a, SOX9, SOX10, TWISTI, and PAX3 by a method known per se. good.
- proteins present on the cell surface of neural crest cells such as CD271 protein (also referred to as “p75(NTR)”) can also be used as neural crest cell-specific markers.
- the neural crest cells are preferably derived from pluripotent stem cells, more preferably iPS cells.
- Pluripotent stem cells include any cells that can be induced into intermediate mesoderm cells that also have proliferative potential.
- pluripotent stem cells include, but are not limited to, embryonic stem (ES) cells, cloned embryo-derived embryonic stem (ntES) cells obtained by nuclear transfer, spermatogonial stem cells (GS cells), and embryonic germ cells.
- EG cells embryonic stem
- iPS induced pluripotent stem
- Muse cells pluripotent stem cells derived from bone marrow stem cells.
- Preferred pluripotent stem cells are iPS cells, more preferably human iPS cells, from the viewpoint that they can be obtained without destroying embryos, ova, etc. in the manufacturing process.
- a method for producing iPS cells is known in the art, and can be produced by introducing a reprogramming factor into any somatic cell.
- the initialization factors are, for example, Oct3/4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15 Genes or gene products such as -2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3 or Glis1 are exemplified, and these reprogramming factors may be used alone or in combination. Also good.
- Combinations of initialization factors include WO2007/069666, WO2008/118820, WO2009/007852, WO2009/032194, WO2009/058413, WO2009/057831, WO2009/075119, WO2009/079007, WO2009/091659, WO2009/091659 101407 ⁇ WO2009/102983 ⁇ WO2009/114949 ⁇ WO2009/117439 ⁇ WO2009/126250 ⁇ WO2009/126251 ⁇ WO2009/126655 ⁇ WO2009/157593 ⁇ WO2010/009015 ⁇ WO2010/033906 ⁇ WO2010/033920 ⁇ WO2010/042800 ⁇ WO2010/050626 ⁇ WO2010/056831 ⁇ WO2010/068955 ⁇ WO2010/098419 ⁇ WO2010/102267 ⁇ WO2010/111409 ⁇ WO2010/111422 ⁇ WO2010/115050 ⁇ WO2010/124290 ⁇ WO2010/147395 ⁇ WO2010/147612 ⁇ Huangfu D, et al.
- Somatic cells include, but are not limited to, fetal (pup) somatic cells, neonatal (pup) somatic cells, and mature healthy or diseased somatic cells, and primary cultured cells. , passaged cells, and cell lines are all included.
- somatic cells include, for example, (1) tissue stem cells (somatic stem cells) such as neural stem cells, hematopoietic stem cells, mesenchymal stem cells, and dental pulp stem cells, (2) tissue progenitor cells, and (3) blood cells (peripheral stem cells).
- lymphocytes epithelial cells, endothelial cells, muscle cells, fibroblasts (skin cells, etc.), hair cells, hepatocytes, gastric mucosa cells, enterocytes, splenocytes, pancreatic cells (pancreatic exocrine cells) etc.), differentiated cells such as brain cells, lung cells, kidney cells and adipocytes.
- the mammal from which somatic cells are collected is not particularly limited, but is preferably human.
- the present invention can provide mesenchymal stem cell differentiation promoting agents containing adrenocortical hormones. By culturing neural crest cells using a medium containing the differentiation-promoting agent, it is possible to increase induction efficiency into mesenchymal stem cells.
- the differentiation-promoting agent of the present invention may consist only of adrenocortical hormones, but may also contain a physiologically acceptable carrier (e.g., physiological isotonic solution (physiological saline, the above-mentioned basal medium, glucose, etc.).
- physiologically acceptable carrier e.g., physiological isotonic solution (physiological saline, the above-mentioned basal medium, glucose, etc.).
- adjuvants e.g., D-sorbitol, D-mannitol, sodium chloride, etc.
- excipients e.g., D-sorbitol, D-mannitol, sodium chloride, etc.
- stabilizers e.g., human serum albumin, polyethylene glycol, etc.
- binders It may also be provided as a composition containing a dissolution aid, a nonionic surfactant, a buffer (e.g., phosphate buffer, sodium acetate buffer), a preservative, an antioxidant, the above-mentioned additives, etc.).
- a buffer e.g., phosphate buffer, sodium acetate buffer
- preservative e.g., an antioxidant, the above-mentioned additives, etc.
- the content of adrenocortical hormone contained in the differentiation-promoting agent of the present invention is such that when the differentiation-promoting agent of the present invention is added to a medium and used, the adrenocortical hormone concentration in the medium is It is preferably configured to contain a concentration sufficient to promote the induction of lineage stem cells.
- the differentiation promoting agent of the present invention is used by being added to a medium in the form of an isotonic aqueous solution, powder, or the like.
- the medium composition of the present invention can be produced by adding adrenocortical hormone to the basal medium, but it can also be used in the form of a kit containing the adrenocortical hormone and the basal medium. That is, the adrenocortical hormone and the basal medium are separately combined and supplied in the form of a kit, and the user adds the adrenocortical hormone to the basal medium at the time of use to prepare and use the medium composition of the present invention. can do.
- the components that make up the basal medium and other components may be provided separately. Both components may be the same or different and may be liquid or powder, and each component may be provided separately, or several components may be provided in a mixed state. Moreover, the kit may not necessarily contain all the components of the medium composition of the present invention, and may omit extremely easily available components such as water. When the component is in the form of powder, it can be used by dissolving in a buffer or the like at the time of use, if desired.
- the present invention provides a method for producing mesenchymal stem cells (hereinafter referred to as a method for producing mesenchymal stem cells), which comprises a step (step 1) of inducing mesenchymal stem cells by culturing neural crest cells in the medium composition of the present invention. , also referred to as the manufacturing method of the present invention).
- a step (step 1) of inducing mesenchymal stem cells by culturing neural crest cells in the medium composition of the present invention. also referred to as the manufacturing method of the present invention.
- differentiation into mesenchymal stem cells is induced by culturing neural crest cells in a medium composition containing a basal medium and adrenocortical hormones.
- By culturing neural crest cells in a medium containing adrenocortical hormones it becomes possible to efficiently differentiate neural crest cells into cells that retain their ability as mesenchymal stem cells.
- the culture in step 1 can be suspension culture, adherent culture, or a combination thereof.
- “Suspension culture” in the present invention refers to culturing cells (or aggregates of cells) while maintaining a state in which they are suspended in a culture solution.
- “Adhesive culture” refers to culture performed under conditions that allow cells (or aggregates of cells) to adhere to culture equipment and the like. In this case, the adhesion of cells means that a strong cell-substratum junction is formed between the cells or cell aggregates and the cultureware.
- suspension culture refers to culture under conditions that do not form strong cell-substrate bonds between cells or cell aggregates and cultureware, etc.
- adherent culture refers to cells or cells This refers to culturing under conditions that form a strong cell-substrate bond between the aggregates and the cultureware.
- the incubator used for floating culture is not particularly limited as long as it is capable of floating culture, and can be appropriately determined by those skilled in the art.
- Such incubators include, for example, flasks, tissue culture flasks, culture dishes (dishes), petri dishes, tissue culture dishes, multidishes, microplates, microwell plates, micropores, multiplates, and multiwell plates.
- chamber slides Petri dishes, tubes, trays, culture bags, Erlenmeyer flasks, spinner flasks or roller bottles.
- These incubators are preferably cell non-adhesive in order to enable suspension culture.
- the surface of the incubator has been artificially treated (for example, superhydrophilic treatment such as MPC polymer, low protein adsorption treatment, etc.) for the purpose of reducing adhesion to cells. You can use things, etc.
- Rotation culture may be performed using a spinner flask, roller bottle, or the like.
- the culture surface of the incubator may be flat-bottomed or uneven.
- the incubator used for adherent culture is not particularly limited as long as it allows adherent culture, and a person skilled in the art can appropriately select an incubator according to the culture scale, culture conditions, and culture period. It is possible to Such incubators include, for example, flasks, tissue culture flasks, culture dishes (dish), tissue culture dishes, multidishes, microplates, microwell plates, multiplates, multiwell plates, chamber slides, Petri dishes, Tubes, trays, culture bags, microcarriers, beads, stack plates, spinner flasks or roller bottles. These incubators are preferably cell-adhesive in order to allow adherent culture.
- Examples of cell-adhesive incubators include incubators whose surface has been artificially treated for the purpose of improving adhesion to cells, specifically surface-treated incubators, or An incubator whose inside is coated with a coating agent is included.
- Surface-treated culture vessels include culture vessels that have been surface-treated, such as by positive charge treatment.
- Coating agents include, for example, laminin [including laminin ⁇ 5 ⁇ 1 ⁇ 1 (hereinafter, laminin 511), laminin ⁇ 1 ⁇ 1 ⁇ 1 (hereinafter, laminin 111), etc.
- laminin 511E8, etc. examples include extracellular matrices such as Max (Corning) and Matrigel, and polymers such as polylysine and polyornithine.
- Neural crest cells that can be used in step 1 are: 1. As described in the medium composition, it may be derived from a living organism or from a pluripotent stem cell. When neural crest cells derived from pluripotent stem cells are used, cells immediately after differentiation into neural crest cells may be used. may be used. Purification as used herein refers to increasing the proportion of a specific type of cell (eg, neural crest cell) in a cell population (eg, a cell population containing neural crest cells).
- a specific type of cell eg, neural crest cell
- the concentration of neural crest cells to be cultured is about 1 ⁇ 10 2 to about 1 ⁇ 10 7 cells/cm 2 , preferably about 3 ⁇ 10 2 to about 5 ⁇ 10 6 cells/cm 2 , more preferably About 4 ⁇ 10 2 to about 2 ⁇ 10 5 cells/cm 2 , more preferably about 4 ⁇ 10 2 to about 1 ⁇ 10 5 cells/cm 2 , even more preferably about 3 ⁇ 10 3 to about 1 ⁇ It can be 10 4 cells/cm 2 .
- the concentration of neural crest cells to be cultured is from about 1 ⁇ 10 2 to about 1 ⁇ 10 7 cells/cm 2 , preferably from about 3 ⁇ 10 2 to about 5 ⁇ 10 6 cells/cm 2 , more preferably.
- Culture conditions such as culture temperature and CO 2 concentration can be appropriately set.
- the culture temperature is, for example, about 30°C to about 40°C, preferably about 37°C.
- the CO2 concentration is for example about 1% to about 10%, preferably about 5%.
- markers for mesenchymal stem cells include CD90, CD44, CD73 and CD105. Therefore, the majority of the mesenchymal stem cell population obtained by the above method (e.g., 60% or more, preferably 70% or more, more preferably 80% or more, still more preferably 90% or more of the cell composition) , most preferably 100% of the cells) are positive for any one of CD90, CD44, CD73 and CD105, preferably a combination of any two, more preferably a combination of three, most preferably all markers preferable. Furthermore, it is more preferable that the cell composition of the present invention does not express molecules whose expression is not observed in mesenchymal stem cells.
- Examples of molecules not found expressed in mesenchymal stem cells include CD34 (expressed in hematopoietic stem cells), CD45 (expressed in hematopoietic stem cells), CD14 (expressed in monocytes and macrophages), CD11b (expressed in monocytes, macrophages, NK cells, granulocytes), CD79 (expressed in B cells), CD19 (expressed in B cells) and HLA-DR (expressed in dendritic cells, B cells, monocytes, macrophages), etc. is mentioned.
- the cell composition of the present invention comprises a majority thereof (e.g., 60% or more, preferably 70% or more, more preferably 80% or more, even more preferably 90% or more, and even More preferably 95% or more, most preferably 100% of the cells) are negative for the expression of molecules whose expression is not observed in mesenchymal stem cells.
- Step A Step of obtaining a cell population containing neural crest cells
- Step B Step of expanding and culturing the cell population obtained in Step A using an extracellular matrix as a scaffold, may be implemented.
- a cell population containing neural crest cells can be obtained by a method known per se.
- the proportion of neural crest cells can vary greatly depending on the tissue collected and conditions for inducing differentiation.
- the percentage of neural crest cells in a cell population containing neural crest cells is, for example, 1-95%, 1-90%, 1-85%, 1-80%, 1-75%, 1 ⁇ 70%, 1 ⁇ 65%, 1 ⁇ 60%, 1 ⁇ 55%, 1 ⁇ 50%, 1 ⁇ 45%, 1 ⁇ 40%, 1 ⁇ 35%, 1 ⁇ 30%, 1 ⁇ 25%, 1 It can be, but is not limited to, ⁇ 20%, 1-15%, or 1-10%.
- the percentage of neural crest cells in the cell population containing neural crest cells is, for example, 25-95%, 25-90%, 25-85%, 25-80%, 25-75%, It can be, but is not limited to, 25-70%, 25-65%, 25-60%, 25-55%, 25-50%, 25-45%, 25-40%, or 25-35%.
- the percentage of neural crest cells in the cell population containing neural crest cells is, for example, 50-95%, 50-90%, 50-85%, 50-80%, 50-75%, It can be, but is not limited to, 50-70%, 50-65%, or 50-60%.
- the percentage of neural crest cells in the cell population containing neural crest cells can be, for example, 70% or more, 75-95%, 75-90%, or 75-85%. is not limited to
- step A The cell population containing neural crest cells obtained in step A may then be subjected to a step of purifying neural crest cells, and further subjected to a step of expanding (the purified neural crest cells). good. That is, step B can also be said to be a step of purifying and expanding neural crest cells.
- expansion culture is a concept that includes culture for maintaining and/or growing desired cells, and preferably culture for growing desired cells.
- the method for purifying neural crest cells is not particularly limited, and examples thereof include single cell conversion, sorting by a cell sorter using a fluorescently labeled neural crest cell-specific antibody, and magnetic beads bound to the antibody. and sorting using an affinity column on which the antibody is immobilized, but not limited thereto.
- the cells are subjected to mechanical dispersing treatment, dispersing treatment using enzymes such as collagenase and trypsin, and/or dispersing treatment using a chelating agent such as EDTA. It may be a cell state.
- a ROCK inhibitor may be added for the purpose of suppressing cell death.
- ROCK inhibitors are not particularly limited as long as they can inhibit the function of Rho-kinase (ROCK), and examples thereof include Y-27632, Fasudil/HA1077, H-1152, Wf-536, and derivatives thereof. be done.
- ROCK inhibitors e.g., US Patent Application Publication Nos. 2005/0209261, 2005/0192304, 2004/0014755, 2004/0002508,. , WO 2004/0002507, WO 2003/0125344, WO 2003/0087919, and WO 2003/062227, WO 2003/059913, WO 2003/062225, WO 2002/076976. 2004/039796).
- a CD271-specific antibody can be used as the neural crest cell-specific antibody.
- step B culture conditions suitable for maintaining and/or growing neural crest cells can be used.
- Culture conditions for expanding and culturing neural crest cells are not particularly limited as long as neural crest cells can be expanded and cultured, and culture conditions known per se can be used.
- One example is a method of culturing in a medium containing a TGF ⁇ inhibitor, EGF (epidermal growth factor) and FGF2 (fibroblast growth factor 2).
- the medium used for expansion culture of neural crest cells can be prepared using the medium used for culturing animal cells as a basal medium.
- basal media include IMDM medium, Medium199 medium, Eagle's Minimum Essential Medium (EMEM) medium, ⁇ MEM medium, Dulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium, StemPro34 (Invitrogen), RPMI-base medium, StemFit (registered trademark) AK03N medium, and mixed medium thereof are included.
- StemFit (registered trademark) medium is preferably used in this step.
- the medium may contain serum or may be serum-free.
- the medium contains, for example, albumin, transferrin, Knockout Serum Replacement (KSR) (serum replacement for FBS during ES cell culture), N2 supplement (Invitrogen), B27 supplement (Invitrogen), fatty acids, insulin, collagen May contain one or more serum replacements such as precursors, trace elements, 2-mercaptoethanol (2ME), thiolglycerol, lipids, amino acids, L-glutamine, Glutamax (Invitrogen), non-essential amino acids, vitamins, It may also contain one or more substances such as growth factors, small molecules, antibiotics, antioxidants, pyruvate, buffers, inorganic salts, and the like.
- KSR Knockout Serum Replacement
- a TGF ⁇ inhibitor is a substance that inhibits signal transduction from binding of TGF ⁇ to a receptor to SMAD, a substance that inhibits binding to the ALK family receptor, or a substance that inhibits SMAD by the ALK family.
- the TGF ⁇ inhibitor is, for example, Lefty-1 (exemplified by NCBI Accession No., mouse: NM_010094, human: NM_020997), SB431542, SB202190 (R.K. Lindemann et al., Mol.
- the TGF ⁇ inhibitor used for expansion culture of neural crest cells can preferably be SB431542.
- the concentration of the TGF ⁇ inhibitor such as SB431542 in the culture medium is not particularly limited as long as it inhibits ALK5, but is preferably 1 nM to 50 ⁇ M.
- the concentration of EGF in the medium is preferably 1 ng/ml to 100 ng/ml, for example, 1 ng/ml, 5 ng/ml, 10 ng/ml, 20 ng/ml, 30 ng/ml, 40 ng/ml, 50 ng/ml, 60 ng/ml, 70 ng/ml, 80 ng/ml, 90 ng/ml, 100 ng/ml, but not limited to these. More preferably, it is 20 ng/ml.
- the concentration of FGF2 in the medium is preferably 1 ng/ml to 100 ng/ml, for example, 1 ng/ml, 5 ng/ml, 10 ng/ml, 20 ng/ml, 30 ng/ml, 40 ng/ml, 50 ng/ml, 60 ng/ml, 70 ng/ml, 80 ng/ml, 90 ng/ml, 100 ng/ml, but not limited to these. More preferably, it is 20 ng/ml.
- components other than the above can also be added to the medium as long as expansion culture of neural crest cells can be achieved.
- the expansion culture of neural crest cells in step B may be either adherent culture or suspension culture, but is preferably performed by adherent culture.
- Step B is characterized by using an extracellular matrix as a scaffold to achieve purification of neural crest cells.
- the term "scaffold” refers to (i) a cell-adhesive culture vessel, its material, a substance existing on the surface of the cell-adhesive culture vessel and constituting an adhesion site, and/or (ii) A substance that dissolves, disperses or suspends in a cell culture medium and forms a three-dimensional network in the cell culture medium, to which cells can adhere to the network.
- cell-adhesive incubators include incubators whose surface is artificially treated for the purpose of improving adhesion to cells, specifically surface-treated incubators, or , an incubator the inside of which is coated with a coating agent.
- Surface-treated culture vessels include culture vessels that have been surface-treated, such as by positive charge treatment.
- Such scaffolds also include substances that coat the surface of culture vessels.
- Coating materials include laminin [including laminin ⁇ 5 ⁇ 1 ⁇ 1 (laminin 511), laminin ⁇ 2 ⁇ 1 ⁇ 1 (laminin 211), laminin ⁇ 1 ⁇ 1 ⁇ 1 (laminin 111), etc. and laminin fragments (laminin 511E8, etc.)], entactin, collagen, gelatin, vitronectin ), synthmax (Corning), extracellular matrices such as Matrigel, or polymers such as polylysine and polyornithine.
- a substance that forms a three-dimensional network in such a cell culture medium exhibits the effect of uniformly suspending cells and/or tissues in a liquid culture medium.
- Nanofibers contained in the medium composition of the present invention include nanofibers obtained by refining a relatively large fibrous structure made of a polymer compound by high-pressure treatment or the like.
- nanofibers form a three-dimensional network that supports cells and tissues, thereby maintaining the cells and tissues in a suspended state.
- the extracellular matrix used as a scaffold to achieve purification of neural crest cells includes laminin or fibronectin, particularly laminin can be full-length laminin, laminin with ⁇ 2 chain, or laminin-211.
- Laminin is a glycoprotein that is a major component of the basement membrane. Laminin is known to be involved in various cell functions such as cell adhesion, cell proliferation, metastasis and differentiation. Laminin is composed of heterotrimers with one each of ⁇ , ⁇ , and ⁇ subunit chains. There are currently 5 types of ⁇ -subunit chains ( ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4, ⁇ 5), 3 types of ⁇ -subunit chains ( ⁇ 1, ⁇ 2, ⁇ 3), and 3 types of ⁇ -subunit chains ( ⁇ 1, ⁇ 2, ⁇ 3) Currently, 15 different laminin isoforms have been identified in humans, depending on the combination of these subunit chains.
- the laminin 211 that can be used in step B can be laminin composed of ⁇ 2, ⁇ 1, and ⁇ 1 subunit chains.
- the origin of laminin is preferably matched with the organism from which the neural crest cells are derived (for example, when human-derived neural crest cells are used, it is preferable to use human-derived laminin 211).
- laminin E8 fragment composed only of integrin-binding site has stronger cell adhesion activity than full-length laminin (Miyazaki T. et al., Nat Commun. 2012;3: 1236)
- the laminin 211 that can be used in step B can be the full length laminin 211 protein rather than a fragment.
- Laminin-211 may be prepared using a gene recombination technique known per se, or commercially available products may be used.
- step B when the cell population is expanded in suspension culture, for example, laminin 211 is contained in the medium, and the floating cells use this as a scaffold to form aggregates, thereby obtaining a three-dimensional What is necessary is just to enable floating culture.
- Floating culture can be performed by a method known per se.
- One example is a method of expanding a cell population in suspension culture in a medium supplemented with laminin 211 while stirring the medium using a spinner flask or the like.
- a cell population can be expanded in suspension culture by combining polysaccharides (e.g., methylcellulose, xanthan gum, gellan gum, etc.) that have the effect of suspending cells when added to the medium, and laminin 211.
- polysaccharides e.g., methylcellulose, xanthan gum, gellan gum, etc.
- the cells spread three-dimensionally and proliferate in a state attached to nanofibers or in a sphere state.
- Cells adhere to the nanofibers and proliferate strongly using them as scaffolds, and as a result, the proliferated cells and cell clusters (spheres, etc.) are arranged on the nanofibers in the shape of grape clusters. Therefore, suspension culture of cells becomes possible.
- the concentration of laminin to be added may be appropriately set in consideration of various conditions such as the seeding density of the cell population and the concentration of the polysaccharide to be used in combination.
- suspension culture means a culture method in which cells are not adhered to the surface of a culture vessel. Suspension culture may or may not be accompanied by physical agitation. Also, the cells to be cultured may be uniformly dispersed in the medium, or may be unevenly dispersed.
- the surface of the culture vessel is coated with laminin 211, for example.
- the coating amount of Laminin 211 is not particularly limited as long as the desired effects of the present invention can be obtained, and a generally recommended coating amount may be used.
- the coating amount of Laminin 211 is 0.1 ng/cm 2 to 1000 ng/cm 2 , preferably 0.5 ng/cm 2 to 500 ng/cm 2 , more preferably 1 ng/cm 2 to 250 ng/cm 2 . 2 , more preferably 2 ng/cm 2 to 100 ng/cm 2 , but not limited thereto.
- culture period in step B may vary depending on the culture conditions, culture method, the ratio of neural crest cells contained in the cell population, etc., purification of neural crest cells is achieved in a relatively short period of time.
- Examples of culture periods include 1 to 21 days, 1 to 20 days, 1 to 19 days, 1 to 18 days, 1 to 17 days, 1 to 16 days, 1 to 15 days, 1 to 14 days, and 1 to 13 days. days, 1-12 days, 1-11 days, 1-10 days, 1-9 days, 1-8 days, 1-7 days, 1-6 days, 1-5 days, 1-4 days, or 1- 3 days, but not limited to.
- the culture temperature in step B is not particularly limited as long as neural crest cells can be cultured, but it is 30 to 40°C, preferably about 37°C.
- the CO 2 concentration during culture in step B is not particularly limited as long as neural crest cells can be cultured, but is 2 to 5%, preferably about 5%.
- Step A Step of obtaining a cell population containing neural crest cells
- Step C Step of expanding and culturing the cell population obtained in Step A using fibronectin as a scaffold, is carried out.
- Neural crest cells can be obtained as described in the media composition . Neural crest cells can occur in the cell population used for manufacturing. Cell populations containing neural crest cells can vary greatly in the ratio of neural crest cells depending on the collected tissue and differentiation induction conditions. In one aspect of the present invention, the percentage of neural crest cells in a cell population containing neural crest cells is, for example, 1-95%, 1-90%, 1-85%, 1-80%, 1-75%, 1 ⁇ 70%, 1 ⁇ 65%, 1 ⁇ 60%, 1 ⁇ 55%, 1 ⁇ 50%, 1 ⁇ 45%, 1 ⁇ 40%, 1 ⁇ 35%, 1 ⁇ 30%, 1 ⁇ 25%, 1 It can be, but is not limited to, ⁇ 20%, 1-15%, or 1-10%.
- the percentage of neural crest cells in the cell population containing neural crest cells is, for example, 25-95%, 25-90%, 25-85%, 25-80%, 25-75%, It can be, but is not limited to, 25-70%, 25-65%, 25-60%, 25-55%, 25-50%, 25-45%, 25-40%, or 25-35%.
- the percentage of neural crest cells in the cell population containing neural crest cells is, for example, 50-95%, 50-90%, 50-85%, 50-80%, 50-75%, It can be, but is not limited to, 50-70%, 50-65%, or 50-60%.
- the percentage of neural crest cells in the cell population containing neural crest cells can be 60% or more, 70% or more, 80% or more, for example, 75-95%, 75-90%, or 75-85%, but is not limited to these.
- cells are passaged as appropriate during step 1. Passaging is performed, for example, every 2-8 days or every 3-7 days after seeding.
- the passage interval is a period of time sufficient for the expansion of the cell aggregates, and a period shorter than the period during which the cell aggregates become too large and it becomes difficult for oxygen and nutrients to reach the cells inside the cell aggregates. preferably done.
- the number of passages during step 1 is, for example, 0 to 20 times (0 times, 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 17 times, 18 times, 19 times, 20 times), preferably 1 to 10 times, more preferably 2 to 8 times is.
- a portion of the cell population may be preserved as a frozen stock after an appropriate number of passages.
- cells are passaged as appropriate during step B or C. Passaging is performed, for example, every 2-8 days or every 3-7 days after seeding.
- the passage interval is a period of time sufficient for the expansion of the cell aggregates, and a period shorter than the period during which the cell aggregates become too large and it becomes difficult for oxygen and nutrients to reach the cells inside the cell aggregates. preferably done.
- the number of passages during step B or C is, for example, 2 to 8 times (2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times), and 3 to 7 times. is preferred, more preferably 4 to 6 times.
- a portion of the cell population may be preserved as a frozen stock after an appropriate number of passages.
- step B or C to step 1 is performed by exchanging the culture medium with the medium composition of the present invention.
- the timing of replacement may be after an appropriate number of passages, or may be during the final passage of step C. For example, 6 hours before the end of the last passage in step B or C is mentioned.
- the present invention provides a production method for producing mesenchymal stem cells from a cell population containing neural crest cells
- the neural crest cells are cells induced to differentiate from pluripotent stem cells
- the cell population is a cell population containing 70% or more of the neural crest cells, 1.25 ⁇ M or more and 300 ⁇ M or less (1.25 ⁇ M to 300 ⁇ M, or 1.25 ⁇ M or more and less than 300 ⁇ M, 1.25 ⁇ M or more and less than 300 ⁇ M, or 1.25 ⁇ M or more and less than 300 ⁇ M) in the presence of adrenocortical hormone culturing under
- a production method for producing mesenchymal stem cells from a cell population containing neural crest cells is provided.
- mesenchymal stem cells are produced by culturing neural crest cells in a medium composition containing adrenocortical hormones.
- the present invention also provides mesenchymal stem cells and cultures thereof thus produced (hereinafter also referred to as mesenchymal stem cells of the present invention and cultures thereof).
- “Culture” refers to the result obtained by culturing cells/cell populations in the production method of the present invention, and includes cells, media, and in some cases cell-secreted components.
- the mesenchymal stem cells of the present invention are characterized by high expression of TSG-6 (Tumor necrosis factor (TNF)- ⁇ stimulated gene-6).
- TSG-6 Tumor necrosis factor (TNF)- ⁇ stimulated gene-6.
- TSG-6 is a member of the hyaluronan-binding protein family, contains a LINK domain that binds to hyaluronan, and its expression is regulated by TNF- ⁇ and IL-1.
- TSG-6 plays a role in regulating matrix composition and structure, regulating interactions between chemokines and cell surfaces, participating in potent anti-inflammatory and tissue protective functions, and has therapeutic effects in a wide range of disease models. is a characteristic marker of mesenchymal stem cells (Day A.J. and Milner C.M., Matrix Biol. 2019 May; 60-83).
- high expression of TSG-6 is high expression in response to IFN ⁇ stimulation.
- the high expression is determined by adding IFN ⁇ to the medium in which the mesenchymal stem cells of the present invention are cultured to stimulate the cells and measuring the expression level of TSG-6 expressed in response to the stimulation. can be detected/quantified by
- the high expression of TSG-6 means that the expression level of TSG-6 by the mesenchymal stem cells of the present invention (/the expression level of TSG-6 by the mesenchymal stem cells of the present invention in response to IFN ⁇ stimulation) is , means that the expression level of TSG-6 is higher than that of other mesenchymal stem cells, specifically bio-derived mesenchymal stem cells, particularly bone marrow-derived mesenchymal stem cells.
- the high expression of TSG-6 in the mesenchymal stem cells of the present invention means that other 2-fold or more, 2.1-fold or more, 2.2-fold or more, 2.3-fold or more, 2.4-fold or more, 2.5-fold or more, 2.6-fold or more, 2.7-fold or more, 2.8-fold or more, than the expression level of TSG-6 by mesenchymal stem cells, It means 2.9 times higher or 3 times higher.
- the TSG-6 protein can be isolated and purified from the mesenchymal stem cells of the present invention by methods well known in the art.
- secretome can be isolated and purified from the mesenchymal stem cells of the present invention by methods well known in the art.
- Secretome is a concept that includes exosomes and extracellular vesicles in general that have undergone various sizes and production processes other than exosomes that may be included during preparation, and protein components contained in cell culture supernatants. be. Exosomes are around 100 nm in size and contain cholesterol, sphingomyelin, ceramide, and lipid raft constituents in their membranes, as well as many proteins, mRNAs, miRNAs, etc. inside. The secretome secreted from the mesenchymal stem cells of the present invention has an antifibrotic effect.
- a preventive or therapeutic agent for inflammatory or fibrotic disease containing the purified secretome as an active ingredient, is also provided.
- the prophylactic or therapeutic agent of the present invention includes, but is not limited to, the mesenchymal stem cells obtained above suspended in physiological saline or an appropriate buffer (eg, phosphate-buffered saline). Obtained by turbidity. In this case, when the number of mesenchymal stem cells obtained is small, they may be cultured and proliferated until a predetermined number of cells is obtained. Cultivation of the obtained mesenchymal stem cells is not particularly limited, but can be performed in a normal growth medium such as DMEM, EMEM, RPMI-1640, F-12, ⁇ -MEM, MSC growing medium (Bio Whittaker). .
- the culture temperature is usually in the range of about 30-40°C, preferably about 37°C.
- the CO 2 concentration is usually in the range of about 1-10%, preferably about 5%.
- Humidity is usually in the range of about 70-100%, preferably about 95-100%.
- DMSO dimethylsulfoxide
- serum albumin etc.
- antibiotics are used to prevent contamination and growth of bacteria. etc.
- cell preparations e.g., carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, preservatives, physiological saline, etc.
- pharmaceutically acceptable ingredients e.g., carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, preservatives, physiological saline, etc.
- One skilled in the art can add these factors and agents to cell preparations at appropriate concentrations.
- the number of mesenchymal stem cells contained in the prophylactic or therapeutic agent prepared above is determined according to the sex, age, weight, affected area, etc. of the subject so that the desired effect can be obtained in the treatment of inflammatory disease or fibrotic disease. It can be appropriately adjusted in consideration of the state of cells, the state of the cells to be used, and the like.
- the target individual includes, but is not limited to, mammals such as humans.
- the cell preparation of the present invention can be administered multiple times (eg, 2 to 10 times) at appropriate intervals (eg, twice a day, once a day, once a week) until the desired therapeutic effect is obtained. twice, once a week, once every two weeks, once a month, once every two months, once every three months, once every six months).
- therapeutically effective doses may include, for example, 1 to 10 doses of 1 ⁇ 10 3 cells to 1 ⁇ 10 10 cells per individual.
- the total amount administered to one individual is not limited, but is 1 ⁇ 10 3 cells to 1 ⁇ 10 11 cells, preferably 1 ⁇ 10 4 cells to 1 ⁇ 10 10 cells, more preferably 1 ⁇ 10 5 cells to 1 ⁇ 10 cells. 9 cells and the like.
- the prophylactic or therapeutic agent for inflammatory diseases of the present invention contains the TSG-6 protein isolated/purified from the mesenchymal stem cells of the present invention as an active ingredient.
- the content of the TSG-6 protein in the prophylactic or therapeutic drug varies depending on the dosage form, dosage of the TSG-6 protein, etc., but is, for example, about 0.1 to 100% by weight.
- the dosage of TSG-6 protein is, but not limited to, 0.01 ng/kg to 1 mg/kg, 10 ng/kg to 100 ⁇ g/kg.
- the preventive or therapeutic agent for fibrotic diseases of the present invention contains the secretome isolated/purified from the mesenchymal stem cells of the present invention as an active ingredient.
- the content of the secretome in the prophylactic or therapeutic drug varies depending on the dosage form, secretome dose, etc., but is, for example, about 0.1 to 100% by weight in terms of protein content.
- the dose of secretome is, but not limited to, 0.01 ng/kg to 1 mg/kg, 10 ng/kg to 100 ⁇ g/kg.
- inflammatory diseases to be prevented or treated by the prophylactic or therapeutic drug for inflammatory diseases of the present invention include hepatitis, liver cirrhosis, Crohn's disease, rheumatoid arthritis, Behcet's disease (eye symptoms), ulcerative colitis, ankylosing Spondylitis, psoriasis (including psoriatic arthritis), HIV infection, multiple myeloma, congestive heart failure, GVHD, giant cell arteritis (GCA), polymyalgia rheumatoid arthritis (PMR), lichen purpura pigmentosa Scoliform dermatitis, sarcoidosis, Wegener's granuloma, pyoderma, Behçet's disease, TNF receptor-associated periodic syndrome (TRAPS), SAPHO syndrome, Takayasu's disease, myositis, Still's disease, periarteritis nodosa (PN), relapse Examples include polychondritis,
- Fibrotic diseases to be prevented or treated by the preventive or therapeutic agents for fibrotic diseases of the present invention include, for example, skin-related scleroderma (localized scleroderma, generalized morphea or linear sclerosis). fibrosis arising from conditions including pseudoscleroderma caused by spinal cord injury, keloid scarring, psoriasis, hypertrophic scarring from burns, atherosclerosis, restenosis, and spinal cord injury; (including glomerulosclerosis, renal tubulointerstitial fibrosis, progressive kidney disease or diabetic nephropathy), cardiac fibrosis (e.g., myocardial fibrosis), pulmonary fibrosis (e.g., glomerulosclerosis pulmonary fibrosis) pulmonary fibrosis, idiopathic pulmonary fibrosis, silicosis, asbestosis, interstitial lung disease, interstitial fibrous lung disease and chemotherapy/radiation-induced pulmonary fibrosis), oral
- the method of administering the prophylactic or therapeutic agent of the present invention is not particularly limited, but suitable examples include intravascular administration (preferably intravenous administration), intraperitoneal administration, intestinal administration, subcutaneous administration, local administration to the affected area, and the like. Among them, intravascular administration and local administration can be exemplified more preferably.
- a method for preventing or treating a disease provides a method for administering to a subject a therapeutically effective amount of the mesenchymal stem cells of the present invention and/or an agent for the prevention or treatment of an inflammatory disease or fibrotic disease of the present invention.
- a method for preventing or treating an inflammatory or fibrotic disease comprising:
- an effective amount means that amount of active ingredient that produces the desired effect.
- therapeutically effective amount means that amount of active ingredient that produces the desired therapeutic effect when administered to a subject.
- a therapeutically effective amount may be administered (implanted) at once or divided into multiple doses (implanted).
- the number of applications for transplantation depends on the disease and is determined by medical practitioners and guidelines. When transplanting multiple times, the interval is not particularly limited, but a period of several days to several weeks may be provided. 4 above. According to the dosage of mesenchymal stem cells etc. described in the preventive or therapeutic agents for diseases .
- animals subject to the cell therapy include rodents such as mice, rats, hamsters and guinea pigs, experimental animals such as rabbits, domestic animals such as pigs, cows, goats, horses, sheep and minks, dogs and cats. and primates such as humans, monkeys, rhesus monkeys, marmosets, orangutans, and chimpanzees, preferably humans.
- the range of disease sites to which the mesenchymal stem cells of the present invention can be applied is appropriately selected depending on the target disease, animal species to be administered, age, sex, body weight, symptoms, and the like.
- the present invention provides a method for producing a drug for the prevention or treatment of diseases containing mesenchymal stem cells as an active ingredient.
- a method for producing a therapeutic agent comprising a step (step 1) of inducing mesenchymal stem cells by culturing neural crest cells in the medium composition of the present invention.
- Step 1 in the method for producing a preventive or therapeutic agent for a disease of the present invention can be performed in the same manner as Step 1 in the method for producing mesenchymal stem cells of the present invention.
- neural crest cells that are induced to differentiate into mesenchymal stem cells, pluripotent stem cells when the neural crest cells are derived from pluripotent stem cells, and pluripotent
- the somatic cells induced into the iPS cells may be either autologous or heterologous (allogeneic or heterologous) to the subject of administration, and the individual that is the source of the cells is not particularly limited, but for example, when the agent of the present invention is produced for administration to an animal in need of disease prevention or treatment, these cells are recipes of mesenchymal stem cells derived from donor cells. It may have tissue compatibility to the extent that it can be engrafted in the ent.
- the drug for prevention or treatment of a disease of the present invention is used for the prevention or treatment of a disease in humans, from the viewpoint of preventing death from being attacked by the immune system, these cells are the patient himself/herself. or obtained from another person with an HLA type that is identical or substantially identical to the patient's HLA type.
- substantially the same HLA type means that when the donor's HLA type is transplanted into a patient with the use of an immunosuppressant or the like, the donor's cell-derived mesenchymal It means that the stem cells match those of the patient to the extent that they are engraftable. Examples thereof include HLA types having the same major HLA (3 main loci of HLA-A, HLA-B and HLA-DR, or 4 loci including HLA-Cw).
- the method for producing a drug for preventing or treating a disease of the present invention includes adding dimethylsulfoxide (DMSO), serum albumin, etc. to protect mesenchymal stem cells, and antibiotics, etc. to prevent bacterial contamination and proliferation. into the medicament.
- DMSO dimethylsulfoxide
- serum albumin etc.
- other pharmaceutically acceptable ingredients e.g., carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, preservatives, physiological saline, etc.
- a drug may be contained in a drug.
- One skilled in the art can add these factors and drugs to the drug at appropriate concentrations.
- the method for producing a preventive or therapeutic agent for inflammatory diseases of the present invention further comprises recovering TSG-6 protein from the induced mesenchymal stem cells and/or the culture supernatant,
- a preventive or therapeutic agent for sexually transmitted diseases contains the TSG-6 protein as an active ingredient.
- the method for producing a preventive or therapeutic agent for fibrotic diseases of the present invention further comprises recovering a secretome from the induced mesenchymal stem cells and/or the culture supernatant, Alternatively, a therapeutic drug contains the secretome as an active ingredient.
- Example 1 Induction of differentiation from iNCCs (iPS cell-derived neural crest cells) to iMSCs (iPS cell-derived mesenchymal stem cells) 1.
- iNCC neural crest cells
- iPS portal iPS portal
- iPS cells were seeded at 6500 cells/well on a 6-well plate coated with laminin 511-E8 fragment (iMatrix511, Nippi) and placed in StemFit (registered trademark) AK03N (Ajinomoto Co.) medium at 37°C. , and cultured for 5 days under 5% CO 2 .
- the medium is StemFit AK03N (solution A + solution B) with SB431542 (Stemgent, Inc., 10 ⁇ M) and CHIR99021 (Wako, 0.3 ⁇ M (condition 1) or 0.9 ⁇ M (condition 2)) in a medium
- SB431542 Stemgent, Inc., 10 ⁇ M
- CHIR99021 Woodo, 0.3 ⁇ M (condition 1) or 0.9 ⁇ M (condition 2)
- Differentiation into neural crest cells was induced for 14 days at 37°C and 5% CO 2 .
- the percentage of neural crest cells at the end of induction was calculated by determining the percentage of cells with high CD271 protein expression using FACS.
- the gene expression status of neural crest cell markers was examined by RT-PCR. The primers used in the RT-PCR method are shown below.
- the cell population containing neural crest cells produced in 1 above was converted to single cells using TrypLE Select (Thermo Fisher).
- the single-celled cell population was seeded on a scaffold-coated 6-well plate and cultured under culture conditions suitable for expansion culture of neural crest cells. More specifically, a medium containing StemFit AK03N (solution A + solution B) supplemented with SB431542 (10 ⁇ M), epithelium growth factor (Sigma Chemical, 20 ng/mL) and StemFit AK03N C solution (Ajinomoto Co., Inc., 0.08%) was cultured at 37°C, 5% CO 2 for 9-10 days. After culturing for 9 to 10 days, when the confluency reached about 90%, the percentage of neural crest cells in the cell population cultured on the scaffold material and the expression status of neural crest cell gene markers were evaluated as described in 1. above. determined by the same method as
- Laminin 211 (Biolamina, 6.3 ng/cm 2 and 62.5 ng/cm 2 ) was used as a scaffold.
- the scaffold was coated on the 6-well plate surface by directly suspending it in the culture medium.
- iNCCs obtained iNCCs (iPSC-derived NCCs) were transferred to a 6-well plate coated with vitronectin-N (Thermo Fisher Scientific) at a density of 1.5 ⁇ g/cm 2 at 5.0 ⁇ 10 3 .
- iMSCs iPSC-derived MSCs were induced by seeding at a cell/well density and culturing for 13 days at 37°C under 5% CO 2 conditions using the following differentiation medium (T3 medium).
- T3 medium StemFit (registered trademark) For Mesenchymal Stem Cells (Ajinomoto Co., Inc.), 90 nM Dexamethasone (Sigma-Aldrich) Surface antigen analysis of 3 MSC positive markers (CD90, CD44, CD73) and 1 negative marker (CD34) was performed on the induced iMSCs using FACS. Table 1 shows the analysis results.
- the obtained cells were positive for CD90, CD44, and CD73, and negative for CD34, confirming iMSC induction.
- Example 2 Analysis of Inflammatory Stimulus Response of iMSCs by IFN ⁇ Stimulation iNCCs were plated at a density of 1.5 ⁇ g/cm 2 onto vitronectin-N coated 6-well plates at a density of 5.0 ⁇ 10 3 cells/well. iMSCs were induced by seeding and culturing for 16 days at 37° C., 5% CO 2 using T3 medium.
- FIG. 1 shows the results of gene expression analysis of TSG-6.
- T3 medium-induced iMSCs were found to significantly increase TSG-6 gene expression upon IFN ⁇ stimulation.
- Example 3 Dexamethasone Concentration Study iNCCs were seeded at a density of 1.5 ⁇ g/cm 2 onto vitronectin-N coated 6-well plates at a density of 3.0 ⁇ 10 4 cells/well and subjected to StemFit® For Dexamethasone was added to Mesenchymal Stem Cells at 50 nM, 100 nM, 1 ⁇ M, 10 ⁇ M and 50 ⁇ M to induce iMSCs under conditions of 37° C. and 5% CO 2 . Eighteen days after initiation of differentiation, each medium was stimulated with 50 ng/mL IFN ⁇ for 48 hours. After stimulation RNA was purified and TNFAIP6 gene expression was analyzed using Real-Time PCR after reverse transcription. FIG.
- FIG. 2 shows cell growth curves during induction of differentiation. In the group to which 50 ⁇ M dexamethasone was added, cell growth stopped after 13 days.
- FIG. 3 shows the results of gene expression analysis of TSG-6. iMSCs induced by addition of 50 nM to 10 ⁇ M of dexamethasone were found to significantly increase TSG-6 gene expression upon IFN ⁇ stimulation.
- Example 4 Examination of types of adrenocortical hormones iMSCs were induced according to Example 1, except that 100 nM Dexamethasone, 100 nM betamethasone, 100 nM prednisolone, and 666 nM prednisolone were used.
- FACS was used to identify 4 MSC-positive markers (CD90, CD44, CD73, CD105), 1 NCC-positive marker (MSC weakly positive marker) (CD271), and 2 MSC-negative markers (CD45 , CD34) surface antigen analysis was performed. Table 3 shows the analysis results.
- prednisolone had a limited effect even when added at 100 nM, but when the titer as a glucocorticoid was adjusted to 666 nM, there was an effect of promoting differentiation.
- the converted concentrations of dexamethasone 50 nM, 90 nM, 100 nM, 1 ⁇ M, 10 ⁇ M, and 50 ⁇ M in this example are 1.333 ⁇ M, 2.3994 ⁇ M, 2.666 ⁇ M, 26.66 ⁇ M, 266.6 ⁇ M, and 1333 ⁇ M, respectively ( converted to a dexamethasone titer of 26.66).
- the converted concentrations of 100 nM and 666 nM prednisolone in this example are 400 nM and 2.664 ⁇ M, respectively (converted with the titer of prednisolone being 4).
- the converted concentration of 100 nM betamethasone in this example is 2.666 ⁇ M (converted based on the betamethasone titer of 26.66).
- i ⁇ SC Secretome Evaluation (Materials and Methods) 1.
- i ⁇ SC secretome collection Secretome is a protein secreted from cells and is known to contain exosomes.
- iMSC frozen stocks at passage number p1 were cultured for 3 passages using StemFit (registered trademark) For Mesenchymal Stem Cell (Ajinomoto Co., Inc.) supplemented with 90 nM Dexamethasone (Sigma-Aldrich). After the medium was changed to DMEM/F-12 (Gibco) medium at 80% confluency, the cells were cultured for 2 days and the culture supernatant was collected. Culture supernatants were 0.22 ⁇ m filtered.
- LX-2 Human Hepatic Stellate Cell Line
- FBS FBS
- penicillin-streptomycin Nacalai
- 2 mM glutamine 2 mM glutamine.
- Gibco was cultured using a medium supplemented with DMEM high glucose (Life Technologies). At passage 4, 4 ⁇ 10 4 cells were seeded into each well of a 12-well plate.
- RT-PCR was performed on the synthesized cDNA using primers from TaqMan (registered trademark) Gene Expression Assays in Table 5.
- the present invention it is possible to provide a medium composition for efficiently inducing mesenchymal stem cells from neural crest cells.
- an efficient method for producing mesenchymal stem cells, a preventive or therapeutic agent for inflammatory or fibrotic diseases containing the mesenchymal stem cells or the like as an active ingredient, and prevention of the disease Alternatively, it is possible to provide a therapeutic method, a method for producing the therapeutic drug, and the like. Therefore, the present invention is extremely useful, for example, in the medical field.
Abstract
Description
[1] 基礎培地及び副腎皮質ホルモンを含有する、神経堤細胞から間葉系幹細胞を誘導するための培地組成物であって、培地組成物中の副腎皮質ホルモンの換算濃度が1.25 μM以上である培地組成物中で神経堤細胞を培養して間葉系幹細胞を誘導する工程を含む、炎症性疾患又は線維性疾患の予防又は治療用薬剤の製造方法。
[2] 該炎症性疾患又は線維性疾患の予防又は治療用薬剤がTSG-6の高発現を特徴とする間葉系幹細胞を有効成分として含有する、[1]に記載の方法。
[3] 炎症性疾患の予防又は治療用薬剤の製造方法であって、誘導された間葉系幹細胞及び/又は培養上清からTSG-6タンパク質を回収することを更に含み、該炎症性疾患の予防又は治療用薬剤がTSG-6タンパク質を有効成分として含有する、[1]に記載の方法。
[4] 線維性疾患の予防又は治療用薬剤の製造方法であって、誘導された間葉系幹細胞及び/又は培養上清からセクレトームを回収することを更に含み、該線維症の予防又は治療用薬剤が、該セクレトームを有効成分として含有する、[1]に記載の方法。
[5] 副腎皮質ホルモンが、糖質コルチコイドあるいはその誘導体である、[1]~[4]のいずれかに記載の製造方法。
[6] 糖質コルチコイドあるいはその誘導体が、酢酸コルチゾン、ヒドロコルチゾン、酢酸フルドロコルチゾン、プレドニゾロン、トリアムシノロン、メチルプレドニゾロン、デキサメタゾン、ベタメタゾン、プロピオン酸ベクロメタゾンから成る群から選択される、少なくとも1種である、[5]に記載の製造方法。
[7] 糖質コルチコイドあるいはその誘導体が、デキサメタゾンである、[5]又は[6]に記載の製造方法。
[8] 培地組成物中の副腎皮質ホルモンの換算濃度が300 μM以下である[1]~[7]のいずれかに記載の製造方法。
[9] 培地組成物中のデキサメタゾンの濃度が10 μM以下である[7]に記載の製造方法。
[10] 基礎培地が無血清培地である、[1]~[9]のいずれかに記載の製造方法。
[11] 神経堤細胞が多能性幹細胞由来である、[1]~[10]のいずれかに記載の製造方法。
[12] 多能性幹細胞が人工多能性幹細胞(iPS細胞)である、[11]に記載の製造方法。
[13] 前記工程の前に以下の工程を実施する、[1]~[12]のいずれかに記載の製造方法:
(工程A)神経堤細胞を含む細胞集団を得る工程、及び
(工程B)工程Aで得られた細胞集団を、細胞外マトリックスを足場として用いて拡大培養する工程。
[14] 細胞外マトリックスが、ラミニンまたはフィブロネクチンである、[13]に記載の製造方法。
[15] ラミニンが、全長ラミニン、α2鎖を有するラミニン又はラミニン211である、[14]に記載の製造方法。
[16] 工程Aで得られた神経堤細胞を含む細胞集団が、神経堤細胞のソーティング処理に供されることなく工程Bに供されることを特徴とする、[13]~[15]のいずれかに記載の製造方法。
[17] 炎症性疾患が肝硬変である、[1]~[3]及び[5]~[16]のいずれかに記載の製造方法。
[18] TSG-6の高発現がIFNγ刺激に応答した高発現である、[2]、[3]及び[5]~[17]のいずれかに記載の製造方法。
[19] [1]~[3]及び[5]~[18]のいずれかの製造方法により製造された、炎症性疾患の予防又は治療用薬剤又は[1]、[2]、[4]~[18]のいずれかの製造方法により製造された、線維性疾患の予防又は治療用薬剤。
本発明は、基礎培地及び副腎皮質ホルモンを含有する、神経堤細胞から間葉系幹細胞を誘導するための培地組成物であって、培地組成物中の副腎皮質ホルモンの換算濃度が1.25 μM以上である培地組成物(以下、本発明の培地組成物とも称する)を提供する。
「神経堤細胞(Neural Crest Cell:「NCC」とも称される)」とは、脊椎動物の初期発生において表皮外胚葉と神経板の間に一時的に形成される神経堤という構造から脱上皮化し、上皮から間葉への転換後に胚体内の様々な部位に誘導される細胞を意味する。本明細書における用語「神経堤細胞」には、生体より採取された細胞のみならず、多能性幹細胞由来の神経堤細胞や、それらを継代した細胞も含まれる。本発明において、神経堤細胞の由来は特に限定されず、いかなる脊椎動物のものであってもよいが、哺乳動物由来の神経堤細胞が好ましい。かかる哺乳動物としては、マウス、ラット、モルモット、ハムスター、ウサギ、ネコ、イヌ、ヒツジ、ブタ、ウシ、ウマ、ヤギ、サル、及びヒトが挙げられるが、これらに限定されない。好ましくはヒトである。
本発明は、本発明の培地組成物中で神経堤細胞を培養して間葉系幹細胞を誘導する工程(工程1)を含む、間葉系幹細胞の製造方法(以下、本発明の製造方法とも称する)を提供する。本発明の製造方法においては、基礎培地及び副腎皮質ホルモンを含む培地組成物中で神経堤細胞を培養することにより、間葉系幹細胞への分化が誘導される。本発明の製造方法によれば、効率よく間葉系幹細胞を製造することが可能である。副腎皮質ホルモンを含む培地中で神経堤細胞を培養することにより、神経堤細胞を間葉系幹細胞としての能力を保持する細胞に効率よく分化させることが可能となる。
ここで純化とは、細胞集団(例えば、神経堤細胞を含む細胞集団)中の特定の種類の細胞(例えば、神経堤細胞)の割合を増加させることをいう。
培養する神経提細胞の濃度は、一態様において、約1×102~約1×107細胞/cm2、好ましくは約3×102~約5×106細胞/cm2、より好ましくは約4×102~約2×105細胞/cm2、更に好ましくは、約4×102~約1×105細胞/cm2、更により好ましくは、約3×103~約1×104細胞/cm2とすることができる。
他の態様において、培養する神経堤細胞の濃度は、約1×102~約1×107細胞/cm2、好ましくは約3×102~約5×106細胞/cm2、より好ましくは約4×102~約2×105細胞/cm2、更に好ましくは、約4×102~約1×105細胞/cm2、更により好ましくは、約1.5×104~約3×104細胞/cm2とすることができる。
(工程A)神経堤細胞を含む細胞集団を得る工程、及び
(工程B)工程Aで得られた細胞集団を、細胞外マトリックスを足場として用いて拡大培養する工程、
が実施されてもよい。
前記ソーティング処理によって純化する方法では、前記神経堤細胞特異的抗体として、例えば、CD271特異的抗体を使用することができる。
かかる細胞接着性の培養器としては、培養器の表面が、細胞との接着性を向上させる目的で人工的に処理された培養器が挙げられ、具体的には表面加工された培養器、又は、内部がコーティング剤で被覆された培養器が挙げられる。表面加工された培養器としては、正電荷処理等の表面加工された培養容器が挙げられる。
かかる足場には、培養容器の表面にコーティングする物質も含まれる。コーティングする物質には、ラミニン[ラミニンα5β1γ1(ラミニン511)、ラミニンα2β1γ1(ラミニン211)、ラミニンα1β1γ1(ラミニン111)等及びラミニン断片(ラミニン511E8等)を含む]、エンタクチン、コラーゲン、ゼラチン、ビトロネクチン(Vitronectin)、シンセマックス(コーニング社)、マトリゲル等の細胞外マトリックス等、又は、ポリリジン、ポリオルニチン等の高分子等が含まれる。
かかる細胞培地中で3次元ネットワークを形成する物質は、液体培地中で、細胞及び/又は組織を均一に浮遊させる効果を示すものである。より詳細には、低分子化合物や高分子化合物が共有結合やイオン結合、静電相互作用や疎水性相互作用、ファンデルワールス力などを介して集合及び自己組織化し液体培地中でナノファイバーを形成したもの、あるいは、高分子化合物からなる比較的大きな線維構造体を高圧処理などにより微細化することにより得られたナノファイバー等が、本発明の培地組成物中に含まれるナノファイバーとして挙げられる。理論には拘束されないが、本発明の培地組成物においては、ナノファイバーが三次元のネットワークを形成し、これが細胞や組織を支えることにより、細胞や組織の浮遊状態が維持される。
(工程A)神経堤細胞を含む細胞集団を得る工程、及び
(工程C)工程Aで得られた細胞集団を、フィブロネクチンを足場として用いて拡大培養する工程、
が実施される。
前記神経堤細胞は、多能性幹細胞から分化誘導された細胞であり、
前記細胞集団は、前記神経堤細胞を70%以上含む細胞集団であり、
前記細胞集団を、1.25 μM以上300 μM以下(1.25 μM~300 μM、又は1.25 μM以上300 μM未満、1.25 μM超300 μM以下、若しくは1.25 μM超300 μM未満)の換算濃度の副腎皮質ホルモンの存在下で培養する工程を含む、
神経堤細胞を含む細胞集団から間葉系幹細胞を製造する製造方法を提供する。
上述のように、副腎皮質ホルモンを含む培地組成物中で神経堤細胞を培養することにより、間葉系幹細胞が製造される。本発明は、かくして製造された間葉系幹細胞及びその培養物も提供する(以下、本発明の間葉系幹細胞、その培養物とも称する)。「培養物」とは、本発明の製造方法において細胞/細胞集団を培養することにより得られる結果物をいい、細胞、培地、場合によっては細胞分泌性成分等が含まれる。
更に、本発明は、本発明の間葉系幹細胞、本発明の間葉系幹細胞から単離/精製されたTSG-6タンパク質又は本発明の間葉系幹細胞から単離/精製されたセクレトームを有効成分として含有する、炎症性疾患又は線維性疾患の予防又は治療用薬剤も提供する。
更に、本発明は、被験体に治療上有効量の本発明の間葉系幹細胞及び/又は本発明の炎症性疾患又は線維性疾患の予防又は治療用薬剤を投与することを含む、炎症性疾患又は線維性疾患の予防又は治療方法を提供する。
本明細書中使用される「治療上有効量」とは、被験体に投与される時、所望の治療効果をもたらす活性成分の量を意味する。治療上有効量は、一度に投与(移植)されてもよく、複数回に分けて投与(移植)されてもよい。移植の適用回数は疾患に応じて医療従事者、ガイドラインに従って決定される。また複数回移植を行う場合、インターバルは特に限定されないが、数日~数週間の期間を置いても良い。上記4.疾患の予防又は治療用薬剤で述べた間葉系幹細胞等の投与量に準じる。
本発明は、間葉系幹細胞を有効成分として含有する炎症性疾患又は線維性疾患の予防又は治療用薬剤の製造方法(以下、本発明の疾患の予防又は治療用薬剤の製造方法)であって、本発明の培地組成物中で神経堤細胞を培養して間葉系幹細胞を誘導する工程(工程1)を含む、方法を提供する。本発明の疾患の予防又は治療用薬剤の製造方法における工程1は、上記本発明の間葉系幹細胞の製造方法の工程1と同様に行うことができる。
1.iPS細胞から神経堤細胞(iNCC)への分化誘導
iPS細胞株として201B7(iPS portal)を用いた。ラミニン511-E8フラグメント(iMatrix511、Nippi)でコートした6ウェルプレートに、iPS細胞を6500細胞/ウェルとなるように播種し、StemFit(登録商標)AK03N(味の素(株))培地中で、37℃、5%CO2下、5日間培養した。次いで、培地をStemFit AK03N(A液+B液)にSB431542(Stemgent, Inc.、10μM)およびCHIR99021(Wako、0.3μM(条件1)または0.9μM(条件2))を添加した培地中にて、37℃、5%CO2下で、14日間神経堤細胞への分化誘導を行った。誘導終了時の神経堤細胞の割合はCD271タンパク質高発現細胞の割合を、FACSを用いて決定することにより算出した。加えて、神経堤細胞マーカーの遺伝子発現状況はRT-PCR法にて調べた。尚、RT-PCR法に用いたプライマーを以下に示す。
TFAP2a Hs00271528_CE A15629
SOX9 Hs01001343_g1 4331182
TWIST1 Hs01675818_s1 4331182
(βactinをレファレンス遺伝子として使用(Hs01101944_s1、4331182))
上記1.で製造した神経堤細胞を含む細胞集団をTrypLE Select(Thermo Fisher)を用いてシングルセル化した。シングルセル化した細胞集団を、足場材でコートした6ウェルプレート上に播種し、神経堤細胞の拡大培養に適した培養条件において培養した。より具体的には、StemFit AK03N(A液+B液)にSB431542(10μM)、Epithelium growth factor(Sigma Chemical、20 ng/mL)およびStemFit AK03N C液(味の素(株)、0.08%)を添加した培地で、37℃、5%CO2下、9~10日間培養した。9~10日間培養後、コンフルエンシーが約90%となった時点で、足場材で培養した細胞集団の神経堤細胞の割合および神経堤細胞遺伝子マーカーの発現状況を上記1.と同様の方法により決定した。
尚、足場材は、培養培地に直接懸濁することにより6ウェルプレート表面上にコーティングした。
得られたiNCC(iPSC由来NCC)を、1.5 μg/cm2の密度でビトロネクチン-N(Thermo Fisher Scientific)コーティングした6ウェルプレートに5.0×103細胞/ウェルの密度で播種し、下記の分化用培地(T3培地)を用いて、37℃、5% CO2条件下で13日間培養し、iMSC(iPSC由来MSC)を誘導した。
T3培地:StemFit(登録商標) For Mesenchymal Stem Cells(味の素(株)), 90 nM Dexamethasone(Sigma-Aldrich)
誘導したiMSCに関して、FACSを用いて、MSCポジティブマーカーを3種類(CD90、CD44、CD73)、ネガティブマーカーを1種類(CD34)の表面抗原解析を実施した。表1に解析結果を示す。
iNCCを、1.5 μg/cm2の密度でビトロネクチン-Nコーティングした6ウェルプレートに5.0×103細胞/ウェルの密度で播種し、T3培地を用いて、37℃、5% CO2条件下で16日間培養し、iMSCを誘導した。
iNCCを、1.5 μg/cm2の密度でビトロネクチン-Nコーティングした6ウェルプレートに3.0×104細胞/ウェルの密度で播種し、StemFit(登録商標) For Mesenchymal Stem Cellsに50 nM、100 nM、1 μM、10 μM、50 μMのDexamethasoneを添加して、37℃、5% CO2条件下でiMSCを誘導した。分化開始18日後に、各培地に50 ng/mL IFNγを添加することで、48時間刺激した。刺激後RNAを精製し、逆転写後Real-Time PCRを用いてTNFAIP6の遺伝子発現を解析した。
図2に分化誘導中の細胞増殖曲線を示す。50 μMのDexamethasoneを添加した群は、13日目以降細胞の増殖が止まった。
図3にTSG-6の遺伝子発現解析結果を示す。50 nMから10 μMのDexamethasoneを添加して誘導したiMSCは、IFNγ刺激により、有意にTSG-6の遺伝子発現が上昇することが認められた。
100 nM Dexamethasone(デキサメタゾン)、100 nM ベタメタゾン、100 nM プレドニゾロン、666 nM プレドニゾロンを用いた以外は、実施例1に従ってiMSCを誘導した。
誘導したiMSCに関して、FACSを用いて、MSC陽性マーカーを4種類(CD90、CD44、CD73、CD105)、NCC陽性マーカー(MSC微陽性マーカー)を1種類(CD271)、MSC陰性マーカーを2種類(CD45、CD34)の表面抗原解析を実施した。表3に解析結果を示す。
本実施例中のプレドニゾロン100 nM、666 nMの換算濃度は、それぞれ400 nM、2.664 μMである(プレドニゾロンの力価を4として換算)。本実施例中のベタメタゾン100 nMの換算濃度は、2.666 μMである(ベタメタゾンの力価を26.66として換算)。
(材料と方法)
1.iМSCのセクレトーム回収
セクレトームは細胞から分泌されるタンパク質で、エクソソームなどを含むことが知られている。継代数p1のiMSC凍結ストックを、90 nM Dexamethasone (Sigma-Aldrich)を加えたStemFit(登録商標) For Mesenchymal Stem Cell(味の素(株))を用いて3継代培養した。80%コンフルエンシーでDMEM/F-12(Gibco) 培地に培地交換した後、2日間培養し、培養上清を回収した。培養上清は、0.22 μm フィルタリングを実施した。その後、Centricon(登録商標) Plus-70のカラムに充填し、3,500×g、25分間遠心することで、限外ろ過を実施した。濃縮した培養上清を回収する際は、カラムを逆さにし1,000×g、2分間遠心することで回収した。得られたセクレトームを表4に示す。
LX-2 Human Hepatic Stellate Cell Line(EDM Millipore、以下、LX-2細胞)を10%FBS(Gibco)、1%ペニシリン・ストレプトマイシン(Nacalai)及び2mM Glutamine(Gibco)をDMEM high Glucose(Life Technologies)に添加した培地を用いて培養した。4継代目に4×104ずつ12ウェルプレートの各ウェルに播種した。培養2日後、10ng/mLのTGF-β1(Peprotech)を添加した培地に、iМSCから得られた濃縮セクレトームを1×の濃度になるようにそれぞれ添加した培地に切り替え、培養を継続した。培地切り替え後2日目に、Accutase(Thermo Fisher)で細胞を剥離し、回収後Maxwell(登録商標) 16 LEV simplyRNA Purification Kits(Promega)を用いてRNAを抽出精製し、PrimeScripttm RT Master Mix(Takara)を用いて逆転写を行った。合成したcDNAについて、表5のTaqMan(登録商標) Gene Expression Assaysの プライマーを用いてRT-PCRを行った。
RT-PCRの結果を図4に示す。LX-2細胞は、TGF-β1刺激により、線維化マーカー遺伝子であるCOL1A1及びACTA2発現を著しく上昇させた。それに対し、DMEM/F12そのものを添加しても特に効果が見られないが、iМSCセクレトームは、TGF-β1刺激で上昇するCOL1A1及びACTA2発現を低下させた。更にiМSCセクレトームはTGF-β1無刺激のLX-2細胞のCOL1A1及びACTA2発現も低下させた。
Claims (19)
- 基礎培地及び副腎皮質ホルモンを含有する、神経堤細胞から間葉系幹細胞を誘導するための培地組成物であって、培地組成物中の副腎皮質ホルモンの換算濃度が1.25 μM以上である培地組成物中で神経堤細胞を培養して間葉系幹細胞を誘導する工程を含む、炎症性疾患又は線維性疾患の予防又は治療用薬剤の製造方法。
- 該炎症性疾患又は線維性疾患の予防又は治療用薬剤がTSG-6の高発現を特徴とする間葉系幹細胞を有効成分として含有する、請求項1に記載の方法。
- 炎症性疾患の予防又は治療用薬剤の製造方法であって、誘導された間葉系幹細胞及び/又は培養上清からTSG-6タンパク質を回収することを更に含み、該炎症性疾患の予防又は治療用薬剤がTSG-6タンパク質を有効成分として含有する、請求項1に記載の方法。
- 線維性疾患の予防又は治療用薬剤の製造方法であって、誘導された間葉系幹細胞及び/又は培養上清からセクレトームを回収することを更に含み、該線維症の予防又は治療用薬剤が、該セクレトームを有効成分として含有する、請求項1に記載の方法。
- 副腎皮質ホルモンが、糖質コルチコイドあるいはその誘導体である、請求項1~4のいずれか1項に記載の製造方法。
- 糖質コルチコイドあるいはその誘導体が、酢酸コルチゾン、ヒドロコルチゾン、酢酸フルドロコルチゾン、プレドニゾロン、トリアムシノロン、メチルプレドニゾロン、デキサメタゾン、ベタメタゾン、プロピオン酸ベクロメタゾンから成る群から選択される、少なくとも1種である、請求項5に記載の製造方法。
- 糖質コルチコイドあるいはその誘導体が、デキサメタゾンである、請求項5又は6に記載の製造方法。
- 培地組成物中の副腎皮質ホルモンの換算濃度が300 μM以下である請求項1~7のいずれか1項に記載の製造方法。
- 培地組成物中のデキサメタゾンの濃度が10 μM以下である請求項7に記載の製造方法。
- 基礎培地が無血清培地である、請求項1~9のいずれか1項に記載の製造方法。
- 神経堤細胞が多能性幹細胞由来である、請求項1~10のいずれか1項に記載の製造方法。
- 多能性幹細胞が人工多能性幹細胞(iPS細胞)である、請求項11に記載の製造方法。
- 前記工程の前に以下の工程を実施する、請求項1~12のいずれか1項に記載の製造方法:
(工程A)神経堤細胞を含む細胞集団を得る工程、及び
(工程B)工程Aで得られた細胞集団を、細胞外マトリックスを足場として用いて拡大培養する工程。 - 細胞外マトリックスが、ラミニンまたはフィブロネクチンである、請求項13に記載の製造方法。
- ラミニンが、全長ラミニン、α2鎖を有するラミニン又はラミニン211である、請求項14に記載の製造方法。
- 工程Aで得られた神経堤細胞を含む細胞集団が、神経堤細胞のソーティング処理に供されることなく工程Bに供されることを特徴とする、請求項13~15のいずれか1項に記載の製造方法。
- 炎症性疾患が肝硬変である、請求項1~3及び5~16のいずれか1項に記載の製造方法。
- TSG-6の高発現がIFNγ刺激に応答した高発現である、請求項2、3及び5~17のいずれか1項に記載の製造方法。
- 請求項1~3及び5~18のいずれか1項の製造方法により製造された、炎症性疾患の予防又は治療用薬剤又は請求項1、2、4~18のいずれか1項の製造方法により製造された、線維性疾患の予防又は治療用薬剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3222761A CA3222761A1 (en) | 2021-06-10 | 2022-03-28 | Method for producing mesenchymal stem cells |
JP2023527533A JPWO2022259721A1 (ja) | 2021-06-10 | 2022-03-28 | |
EP22819909.7A EP4353243A1 (en) | 2021-06-10 | 2022-03-28 | Method for producing mesenchymal stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-097619 | 2021-06-10 | ||
JP2021097619 | 2021-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022259721A1 true WO2022259721A1 (ja) | 2022-12-15 |
Family
ID=84425187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/015032 WO2022259721A1 (ja) | 2021-06-10 | 2022-03-28 | 間葉系幹細胞の製造方法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4353243A1 (ja) |
JP (1) | JPWO2022259721A1 (ja) |
CA (1) | CA3222761A1 (ja) |
WO (1) | WO2022259721A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117431209A (zh) * | 2023-12-22 | 2024-01-23 | 上海元戊医学技术有限公司 | 通过神经嵴细胞系制备间充质干细胞的方法及作为骨关节炎药物的应用 |
Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076976A2 (en) | 2001-03-23 | 2002-10-03 | Bayer Corporation | Rho-kinase inhibitors |
US20030087919A1 (en) | 2001-03-23 | 2003-05-08 | Bayer Corporation | Rho-kinase inhibitors |
WO2003059913A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
WO2003062225A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
WO2003062227A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
WO2004039796A1 (de) | 2002-10-28 | 2004-05-13 | Bayer Healthcare Ag | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2009007852A2 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc | Multipotent/pluripotent cells and methods |
WO2009032194A1 (en) | 2007-08-31 | 2009-03-12 | Whitehead Institute For Biomedical Research | Wnt pathway stimulation in reprogramming somatic cells |
WO2009057831A1 (ja) | 2007-10-31 | 2009-05-07 | Kyoto University | 核初期化方法 |
WO2009058413A1 (en) | 2007-10-29 | 2009-05-07 | Shi-Lung Lin | Generation of human embryonic stem-like cells using intronic rna |
WO2009075119A1 (ja) | 2007-12-10 | 2009-06-18 | Kyoto University | 効率的な核初期化方法 |
WO2009079007A1 (en) | 2007-12-17 | 2009-06-25 | Gliamed, Inc. | Stem-like cells and method for reprogramming adult mammalian somatic cells |
WO2009091659A2 (en) | 2008-01-16 | 2009-07-23 | Shi-Lung Lin | Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents |
WO2009101084A1 (en) | 2008-02-13 | 2009-08-20 | Fondazione Telethon | Method for reprogramming differentiated cells |
WO2009102983A2 (en) | 2008-02-15 | 2009-08-20 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2009101407A2 (en) | 2008-02-11 | 2009-08-20 | Cambridge Enterprise Limited | Improved reprogramming of mammalian cells, and the cells obtained |
WO2009114949A1 (en) | 2008-03-20 | 2009-09-24 | UNIVERSITé LAVAL | Methods for deprogramming somatic cells and uses thereof |
WO2009117439A2 (en) | 2008-03-17 | 2009-09-24 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
WO2009126655A2 (en) | 2008-04-07 | 2009-10-15 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator |
WO2009146408A1 (en) | 2008-05-30 | 2009-12-03 | Summa Health Systems Llc | Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions |
WO2009157593A1 (en) | 2008-06-27 | 2009-12-30 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2010009015A2 (en) | 2008-07-14 | 2010-01-21 | Oklahoma Medical Research Foundation | Production of pluripotent cells through inhibition of bright/arid3a function |
WO2010033920A2 (en) | 2008-09-19 | 2010-03-25 | Whitehead Institute For Biomedical Research | Compositions and methods for enhancing cell reprogramming |
WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2010042800A1 (en) | 2008-10-10 | 2010-04-15 | Nevada Cancer Institute | Methods of reprogramming somatic cells and methods of use for such cells |
WO2010050626A1 (en) | 2008-10-30 | 2010-05-06 | Kyoto University | Method for producing induced pluripotent stem cells |
WO2010056831A2 (en) | 2008-11-12 | 2010-05-20 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator |
WO2010068955A2 (en) | 2008-12-13 | 2010-06-17 | Dna Microarray | MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING |
WO2010098419A1 (en) | 2009-02-27 | 2010-09-02 | Kyoto University | Novel nuclear reprogramming substance |
WO2010102267A2 (en) | 2009-03-06 | 2010-09-10 | Ipierian, Inc. | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
WO2010111422A2 (en) | 2009-03-25 | 2010-09-30 | The Salk Institute For Biological Studies | Induced pluripotent stem cell generation using two factors and p53 inactivation |
WO2010111409A2 (en) | 2009-03-25 | 2010-09-30 | The Salk Institute For Biological Studies | Pluripotent stem cells |
WO2010115050A2 (en) | 2009-04-01 | 2010-10-07 | The Regents Of The University Of California | Embryonic stem cell specific micrornas promote induced pluripotency |
WO2010124290A2 (en) | 2009-04-24 | 2010-10-28 | Whitehead Institute For Biomedical Research | Compositions and methods for deriving or culturing pluripotent cells |
WO2010147395A2 (en) | 2009-06-16 | 2010-12-23 | Korea Research Institute Of Bioscience And Biotechnology | Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
WO2018123968A1 (ja) * | 2016-12-28 | 2018-07-05 | 株式会社ツーセル | 生体組織損傷の修復剤および当該修復剤の製造方法 |
WO2019107485A1 (ja) * | 2017-11-30 | 2019-06-06 | 国立大学法人京都大学 | 細胞の培養方法 |
WO2020230832A1 (ja) * | 2019-05-15 | 2020-11-19 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
JP2021097619A (ja) | 2019-12-20 | 2021-07-01 | 株式会社クボタ | 農業機械 |
-
2022
- 2022-03-28 WO PCT/JP2022/015032 patent/WO2022259721A1/ja active Application Filing
- 2022-03-28 JP JP2023527533A patent/JPWO2022259721A1/ja active Pending
- 2022-03-28 CA CA3222761A patent/CA3222761A1/en active Pending
- 2022-03-28 EP EP22819909.7A patent/EP4353243A1/en active Pending
Patent Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076976A2 (en) | 2001-03-23 | 2002-10-03 | Bayer Corporation | Rho-kinase inhibitors |
US20030087919A1 (en) | 2001-03-23 | 2003-05-08 | Bayer Corporation | Rho-kinase inhibitors |
US20030125344A1 (en) | 2001-03-23 | 2003-07-03 | Bayer Corporation | Rho-kinase inhibitors |
WO2003059913A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
US20040014755A1 (en) | 2002-01-10 | 2004-01-22 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
WO2003062225A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
WO2003062227A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
US20040002507A1 (en) | 2002-01-23 | 2004-01-01 | Bayer Corporation | Rho-kinase inhibitors |
US20040002508A1 (en) | 2002-01-23 | 2004-01-01 | Bayer Corporation | Rho-kinase inhibitors |
US20050192304A1 (en) | 2002-01-23 | 2005-09-01 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
US20050209261A1 (en) | 2002-01-23 | 2005-09-22 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
WO2004039796A1 (de) | 2002-10-28 | 2004-05-13 | Bayer Healthcare Ag | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2009007852A2 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc | Multipotent/pluripotent cells and methods |
WO2009032194A1 (en) | 2007-08-31 | 2009-03-12 | Whitehead Institute For Biomedical Research | Wnt pathway stimulation in reprogramming somatic cells |
WO2009058413A1 (en) | 2007-10-29 | 2009-05-07 | Shi-Lung Lin | Generation of human embryonic stem-like cells using intronic rna |
WO2009057831A1 (ja) | 2007-10-31 | 2009-05-07 | Kyoto University | 核初期化方法 |
WO2009075119A1 (ja) | 2007-12-10 | 2009-06-18 | Kyoto University | 効率的な核初期化方法 |
WO2009079007A1 (en) | 2007-12-17 | 2009-06-25 | Gliamed, Inc. | Stem-like cells and method for reprogramming adult mammalian somatic cells |
WO2009091659A2 (en) | 2008-01-16 | 2009-07-23 | Shi-Lung Lin | Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents |
WO2009101407A2 (en) | 2008-02-11 | 2009-08-20 | Cambridge Enterprise Limited | Improved reprogramming of mammalian cells, and the cells obtained |
WO2009101084A1 (en) | 2008-02-13 | 2009-08-20 | Fondazione Telethon | Method for reprogramming differentiated cells |
WO2009102983A2 (en) | 2008-02-15 | 2009-08-20 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2009117439A2 (en) | 2008-03-17 | 2009-09-24 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
WO2009114949A1 (en) | 2008-03-20 | 2009-09-24 | UNIVERSITé LAVAL | Methods for deprogramming somatic cells and uses thereof |
WO2009126655A2 (en) | 2008-04-07 | 2009-10-15 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator |
WO2009126250A2 (en) | 2008-04-07 | 2009-10-15 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through rna interference |
WO2009126251A2 (en) | 2008-04-07 | 2009-10-15 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator |
WO2009146408A1 (en) | 2008-05-30 | 2009-12-03 | Summa Health Systems Llc | Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions |
WO2009157593A1 (en) | 2008-06-27 | 2009-12-30 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2010009015A2 (en) | 2008-07-14 | 2010-01-21 | Oklahoma Medical Research Foundation | Production of pluripotent cells through inhibition of bright/arid3a function |
WO2010033920A2 (en) | 2008-09-19 | 2010-03-25 | Whitehead Institute For Biomedical Research | Compositions and methods for enhancing cell reprogramming |
WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2010042800A1 (en) | 2008-10-10 | 2010-04-15 | Nevada Cancer Institute | Methods of reprogramming somatic cells and methods of use for such cells |
WO2010050626A1 (en) | 2008-10-30 | 2010-05-06 | Kyoto University | Method for producing induced pluripotent stem cells |
WO2010056831A2 (en) | 2008-11-12 | 2010-05-20 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator |
WO2010068955A2 (en) | 2008-12-13 | 2010-06-17 | Dna Microarray | MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING |
WO2010098419A1 (en) | 2009-02-27 | 2010-09-02 | Kyoto University | Novel nuclear reprogramming substance |
WO2010102267A2 (en) | 2009-03-06 | 2010-09-10 | Ipierian, Inc. | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
WO2010111422A2 (en) | 2009-03-25 | 2010-09-30 | The Salk Institute For Biological Studies | Induced pluripotent stem cell generation using two factors and p53 inactivation |
WO2010111409A2 (en) | 2009-03-25 | 2010-09-30 | The Salk Institute For Biological Studies | Pluripotent stem cells |
WO2010115050A2 (en) | 2009-04-01 | 2010-10-07 | The Regents Of The University Of California | Embryonic stem cell specific micrornas promote induced pluripotency |
WO2010124290A2 (en) | 2009-04-24 | 2010-10-28 | Whitehead Institute For Biomedical Research | Compositions and methods for deriving or culturing pluripotent cells |
WO2010147395A2 (en) | 2009-06-16 | 2010-12-23 | Korea Research Institute Of Bioscience And Biotechnology | Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
WO2018123968A1 (ja) * | 2016-12-28 | 2018-07-05 | 株式会社ツーセル | 生体組織損傷の修復剤および当該修復剤の製造方法 |
WO2019107485A1 (ja) * | 2017-11-30 | 2019-06-06 | 国立大学法人京都大学 | 細胞の培養方法 |
WO2020230832A1 (ja) * | 2019-05-15 | 2020-11-19 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
JP2021097619A (ja) | 2019-12-20 | 2021-07-01 | 株式会社クボタ | 農業機械 |
Non-Patent Citations (21)
Title |
---|
"NCBI", Database accession no. NM_010094 |
CHUNG KUEI-FANG, SICARD FLAVIE, VUKICEVIC VLADIMIR, HERMANN ANDREAS, STORCH ALEXANDER, HUTTNER WIELAND B., BORNSTEIN STEFAN R., EH: "Isolation of Neural Crest Derived Chromaffin Progenitors from Adult Adrenal Medulla", STEM CELLS, vol. 27, no. 10, 1 October 2009 (2009-10-01), pages 2602 - 2613, XP093014200, ISSN: 1066-5099, DOI: 10.1002/stem.180 * |
DAY A.J.MILNER C.M., MATRIX BIOL, May 2019 (2019-05-01), pages 60 - 83 |
EMINLI S ET AL., STEM CELLS., vol. 26, 2008, pages 2467 - 2474 |
FENG B ET AL., NAT. CELL BIOL., vol. 11, 2009, pages 197 - 203 |
FUKUTA M. ET AL., PLOS ONE., vol. 9, no. 12, 2 December 2014 (2014-12-02), pages 112291 |
HAN J ET AL., NATURE, vol. 463, 2010, pages 1096 - 100 |
HENG JC ET AL., CELL STEM CELL, vol. 6, 2010, pages 167 - 74 |
HUANGFU D ET AL., NAT. BIOTECHNOL., vol. 26, 2008, pages 1269 - 1275 |
ICHIDA JK ET AL., CELL STEM CELL, vol. 5, 2009, pages 491 - 503 |
KIM JB ET AL., NATURE, vol. 461, 2009, pages 649 - 643 |
LINDEMANN ET AL., MOL. CANCER, vol. 2, 2003, pages 20 |
LYSSIOTIS CA ET AL., PROC NATL ACAD SCI U S A., vol. 106, 2009, pages 8912 - 8917 |
MAEKAWA M ET AL., NATURE, vol. 47, no. 4, 2011, pages 225 - 9 |
MALI P ET AL., STEM CELLS., vol. 28, 2010, pages 713 - 720 |
MINAMINO, YUKI ET AL.: "Differentiation of neural crest cells from spheres of mouse ES cells cultured in a serum-free culture", SHIKA IGAKU - JOURNAL OF THE OSAKA ODONTOLOGICAL SOCIETY, OSAKA SHIKA GAKKAI, OSAKA,, JP, vol. 75, no. 2, 1 January 2012 (2012-01-01), JP , pages 65 - 69, XP009542180, ISSN: 0030-6150 * |
MIYAZAKI T. ET AL., NAT COMMUN., vol. 3, 2012, pages 1236 |
R.L. JUDSON ET AL., NAT. BIOTECHNOL., vol. 27, 2009, pages 459 - 461 |
VOGEL, K.S. ; WESTON, J.A.: "The sympathoadrenal lineage in avian embryos - II. Effects of glucocorticoids on cultured neural crest cells", DEVELOPMENTAL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 139, no. 1, 1 May 1990 (1990-05-01), AMSTERDAM, NL , pages 13 - 23, XP024851574, ISSN: 0012-1606, DOI: 10.1016/0012-1606(90)90274-M * |
ZHAO C.IKEYA M., STEM CELLS INT., 31 July 2018 (2018-07-31) |
ZHAO Y ET AL., CELL STEM CELL, vol. 3, 2008, pages 132 - 135 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117431209A (zh) * | 2023-12-22 | 2024-01-23 | 上海元戊医学技术有限公司 | 通过神经嵴细胞系制备间充质干细胞的方法及作为骨关节炎药物的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP4353243A1 (en) | 2024-04-17 |
JPWO2022259721A1 (ja) | 2022-12-15 |
CA3222761A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6588005B2 (ja) | 軟骨形成を刺激するために使用される医薬組成物 | |
TWI698242B (zh) | 利用血管母細胞產生間葉基質細胞之方法 | |
AU2001238695B2 (en) | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof | |
US20220090008A1 (en) | Colony forming medium and use thereof | |
JP6486948B2 (ja) | 純粋栄養膜層から由来した幹細胞及びそれを含む細胞治療剤 | |
AU2001238695A1 (en) | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof | |
JP6592551B2 (ja) | 免疫調節活性を有する細胞集団、その調製方法、及び、その使用 | |
JP6193214B2 (ja) | 歯髄由来の多能性幹細胞の製造方法 | |
TW201809269A (zh) | 細胞培養用培養基及細胞培養方法 | |
Wang et al. | Human umbilical cord mesenchymal stem cells: subpopulations and their difference in cell biology and effects on retinal degeneration in RCS rats | |
JP2013507945A (ja) | 免疫調節活性を有する細胞集団、その製造方法及び使用 | |
WO2022259721A1 (ja) | 間葉系幹細胞の製造方法 | |
JP2012510279A (ja) | 脂肪由来幹細胞の産生方法および疾患の治療における当該細胞の使用 | |
TWI419970B (zh) | 使成體幹細胞產生為一球體細胞群體的方法 | |
JP2022189188A (ja) | 間葉系幹細胞の製造方法 | |
Sánchez-Sánchez et al. | Development of hydrogel with anti-inflammatory properties permissive for the growth of human adipose mesenchymal stem cells | |
JP2012044914A (ja) | 幹細胞の未分化維持剤及び増殖促進剤 | |
US9982232B2 (en) | Methods of generating cells with multilineage potential | |
KR102275454B1 (ko) | 전능성 줄기세포로부터 중간엽 줄기세포를 분화시키는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22819909 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023527533 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3222761 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022819909 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022819909 Country of ref document: EP Effective date: 20240110 |